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1.1 Introduction
Endovascular aneurysm repair (EVAR) is here to stay. From its inception in the early
1990's, EVAR has evolved from a risky experiment into a well established alterna-
tive for open aneurysm repair (OR). In the last decade of the previous century, vas-
cular surgery was in transit from conventional open operations to less invasive tech-
niques. EVAR was maybe the first alternative method that made vascular surgeons
aware of the shifting paradigm in their field. As a result, the introduction of this new
therapy was rather controversial. While quickly embraced by some, it was heavily
criticised as 'a failed experiment' by others.
1
By the turn of the century, more than 20.000 endovascular procedures were per-
formed worldwide.  New, improved devices are still being developed and currently
three endoprostheses are approved by the US Food and Drug Administration (FDA).
Although EVAR was designed originally for patients unfit for open repair, very soon
it was considered as the first choice treatment by many surgeons. Clear scientific
evidence, however, demonstrating EVAR to be superior to conventional open repair
had never been obtained.
The best evidence available was derived from the results of four prospective
concurrent controlled trials.
2-5
All these studies reported that, as compared to open
repair, EVAR results in reduced operative morbidity rates, reduction in length of stay
and shorter recovery time. However, none of these four studies had shown a signif-
icant improvement in operative mortality. Two large retrospective population based
studies, demonstrated a significant reduction in operative mortality after EVAR.
6,7
Clearly, a randomised comparison was due as even large population based obser-
vational studies can be biased by differences between the groups. 
'Which is better for patients suitable for both treatments:
Endovascular or open repair?'
There are several ways of answering this question.
• From the patient's perspective, short term results like mortality and complica-
tion rates are very important. However, the impact on quality of life and long-
term durability will also play a crucial role. 
• From an economic perspective, the financial implications of EVAR, as compared
to the costs of OR need consideration. 
• From a policy perspective, costs should be balanced with the effects of the new
treatment. Cost-effectiveness is an important issue for decision makers on reim-
bursement.
1.2 Objective and outline of this thesis 
The main objective of this thesis is to provide an answer to all aspects of the above
question. We conducted a randomised multicenter trial, comparing elective
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endovascular and open repair of abdominal aortic aneurysms in patients suitable
for both treatments: The Dutch Randomised Endovascular Aneurysm Management
(DREAM)-trial.
The impact of endovascular treatment on in-hospital mortality of non-ruptured
abdominal aortic aneurysm (AAA) repair was assessed prior to initiating the trial
(chapter 2). The hypothesis that the introduction of EVAR has contributed to
improved results of non-ruptured AAA treatment was tested by analysing the
nation-wide outcome of non-ruptured AAA repair over one decade (1991-2000). 
As the results of this retrospective analysis showed a positive impact of the
introduction of EVAR on mortality rates, the need for a randomised trial became
even clearer. The background, design and methods of this randomised trial are
described in chapter 3.
Randomised clinical trials should be monitored carefully during their conduct.
Early evidence of clear treatment benefit or harm must result in an immediate halt
to the study to prevent further patients from being randomised and potentially
exposed to an inferior treatment. In chapter 4 the benefits of performing continu-
ous sequential monitoring of safety are described. 
Chapter 5 describes the primary endpoint of the DREAM-trial.
From a surgical perspective technical results determine the success of a treat-
ment. However from the patient's perspective, the impact on quality of life is of
utmost importance. A few studies have been published about this subject, demon-
strating contradicting results.
8-10
However, none of these studies used a randomised
comparison. We compared quality of life and sexual function in the first postopera-
tive year after EVAR and OR (chapter 6 & 7) in a randomised trial.
In addition to the evaluation of health benefits, it is important to consider the
economic and health related quality of life implications of EVAR as compared to
OR. Not only short-term costs, but also costs of follow-up and reinterventions in
relation to the clinical effects need to be considered. In chapter 8, the costs and
cost effectiveness in the first postoperative year of EVAR and OR are compared.
Worldwide, besides the DREAM-trial three other randomised trials have com-
menced; the UK EVAR-1 (endovascular aneurysm management) trial, the USA
OVER (open versus endovascular repair) trial and the France ACE-trial (the
Anévrisme de l'aorte abdominale: Chirurgie versus Endoprothèse). The last two tri-
als are still running. The 30-day results of the EVAR-1 trial were published in the
same time period of the DREAM-trial. In chapter 9 we performed a meta-analysis
of the results of the DREAM-trial and the EVAR-1 trial.
In chapter 10, the mid-term results of the DREAM are analysed to investigate
whether the survival difference as described in chapter 5 is sustained beyond the
perioperative period.  
Chapter 11 contains the general discussion.
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Abstract
Background
We hypothesised that over the past decade, the nation-wide outcome of infrarenal
abdominal aortic aneurysm (AAA) repair has improved with the introduction of
endovascular treatment. The aim of the study was to identify endovascularly-treat-
ed patients in a national registry and to assess the impact on in-hospital mortality
of non-ruptured AAA repair, if any, after the introduction of endovascular repair. 
Methods
We retrospectively studied the nation-wide outcome of non-ruptured AAA repair
over the past decade. Variables studied were age and gender of the patients, hos-
pital size and type and the year in which treatment was performed and the out-
come on in-hospital mortality. 
Results
The in-hospital mortality of non-ruptured AAA repair in 16,446 patients in the 10-
year period from 1991 to 2000 was 7.3% (6.2-8.2%). In the 15,589 (95%) patients
that underwent conventional treatment, in-hospital mortality was 7.6% (7.0-8.1%),
whereas in the endovascular group it was 1.9% (0.6-3.5%). In the multivariate
analysis, age and endovascular repair were the most important independent pre-
dictors of in-hospital mortality. 
Conclusion
With the limitations of a national registry aside, the introduction of endovascular
aneurysm repair seems to have had a small but significant impact on in-hospital
mortality following infrarenal AAA repair.
17
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2.1. Introduction
Elective repair of asymptomatic abdominal aortic aneurysm (AAA), carries a mor-
tality rate of between 5 and 10%. The goal of excluding the aneurysm prior to the
symptomatic stage, preceding rupture, is obvious. The chance of rupture is propor-
tional to the diameter of the aneurysm, increasing markedly with larger diameters.
1
Despite incidentally reported excellent figures on outcome following aortic
aneurysm surgery, the objective operative mortality is reflected more accurately in
population-based series. Although single center studies on mortality following
endovascular AAA repair are available,
2-4
to our knowledge no population-based
reports on mortality following endovascular treatment of infrarenal AAAs have
been published. 
We hypothesised that, over the past decade, endovascular treatment has con-
tributed to improved results of non-ruptured AAA treatment. 
In this study, we analysed nation-wide in-hospital mortality of conventional open
and endovascular treatment of non-ruptured infrarenal aortic aneurysm over the
past decade in which endovascular repair was introduced. 
2.2. Materials and Methods
All patients admitted with the primary indication for treatment of a non-ruptured
infrarenal AAA in The Netherlands from 1991 through to the year 2000 were
0
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Figure 1
Number of intact infrarenal abdominal aortic aneurysm repairs performed in The Netherlands in the last
decade according to the type of treatment (conv, open surgical repair; endo, endovascular repair).
included in the study. Data were obtained from Prismant-The Institute for Health
Care Management (Utrecht, The Netherlands). This is a national registry for
medical diagnoses and procedures. All hospitals in The Netherlands where aortic
aneurysm repair is performed report to this national registration foundation.
Anonymous individual information was obtained including the age and gender of
the patients, date of treatment, hospital class (0-399 beds, >400 beds and univer-
sity hospitals) and outcome of treatment in (in-hospital) mortality. 
Elective treatment of asymptomatic infrarenal aortic aneurysm is not coded as
such, but is included in the broader group of 'infrarenal AAA, without mention of
rupture'. Consequently, this code includes impending rupture of symptomatic, but
intact, aneurysms. Emergency surgery for ruptured aneurysms carries a different
code. 
The Prismant registry does not differentiate between endovascular and conven-
tional surgery. The endovascular procedures in the study group were identified
using Eurostar and Medtronic records. The Medtronic database was used because
a few centers in the Netherlands did not report to Eurostar. The vast majority of the
endografts used in these centers were Medtronic devices. By combining the
Eurostar and Medtronic databases almost all endografts carried out in the study-
period were identified. For further verification, institutional databases from select-
ed centers were individually analysed and subsequently matched with the Prismant
population database. Eurostar is a European registry recording endovascular pro-18
C
H
A
P
T
E
R
2
All
Conv
Endo
              
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
0,0%
2,0%
4,0%
6,0%
8,0%
10,0%
Figure 2
In-hospital mortality in 16,446 patients following intact infrarenal abdominal aortic aneurysm repair over a
decade, regarding the entire studied group (All) and subdivided into the type of treatment performed (conv,
open surgical repair; endo, endovascular repair). Bars represent the 95% confidence intervals.
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cedures performed in most European countries and is an initiative of vascular sur-
geons. The Medtronic database is an industrial registry for endovascular proce-
dures. 
Operative in-hospital mortality was defined as death following treatment dur-
ing hospital admission, irrespective of the cause of death. For univariate analysis,
the ANOVA-test was used. 
In-hospital mortality was also analysed using a multiple linear regression analy-
sis with stepwise, backward removal of variables. The criterion of removal used was
a probability of F-to-remove >0.100. Variables entered were the type (open versus
endovascular) and year of treatment, patient age, gender, and hospital size and
type. The statistical package used was SPSS 11.01 for Windows. 
2.3. Results
In the 10-year period from 1991 to 2000, 16,446 patients underwent repair for a
non-ruptured infrarenal AAA in The Netherlands. There were 14,462 men (88%)
and 1984 (12%) women. The overall in-hospital mortality rate was 7.3% (1207 of
16,446 patients) and varied between 6.2% in 1999 (101 of 1639 patients) and
8.2% in 1991 (123 of 1494 patients). Up to the year 1994, no endovascular AAA
repairs were performed in The Netherlands. Beginning in 1994 the number of
endovascular aortic aneurysm repairs gradually increased up to 277 per year in
2000 (Figure 1). From 1994 through to the year 2000, a total of 857 patients under-
0,0%
2,0%
4,0%
6,0%
8,0%
10,0%
12,0%
14,0%
16,0%
18,0%
20,0%
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
<400
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Univ
Figure 3
In-hospital mortality in 16,446 patients following intact infrarenal abdominal aortic aneurysm repair over a
decade, regarding the type of hospital in which treatment was performed (0-399 beds; >400 beds; University
hospitals). Bars represent the 95% confidence intervals.
went endovascular infrarenal aortic aneurysm repair. The average in-hospital mor-
tality of endovascular treatment was 1.9%, ranging from 0.6% in 1998 (one of 161
patients) to 3.5% in 2000 (10 of 287 patients). The average in-hospital mortality of
conventional treatment was 7.6% (1191 of 15,589 patients), varying from 7.0% in
1999 (98 of 1397 patients) to 8.1% in the year 2000 (104 out of 1283 patients). In
figure 2, the impact of the increasing number of endovascular repairs can be
appreciated by the deviating mortality rates of all aneurysm repairs versus conven-
tional repairs. Mortality for the different hospital classes was 6.5% (95% confidence
interval (CI): 5.7-7.4%) for the category 0-399 beds, 7.6% (7.1-8.1%) for >400 beds
and 7.4% (6.3-8.6%) for University Hospitals (F=2.0; p=0.13). Yearly differences of
mortality between hospital classes were considerable, but no significant trends over
time were found (Figure 3). Figure 4 depicts the number of procedures in five age
groups for both males and females: 82% of the procedures were performed on
patients between 60 and 79 years of age. Mortality increased with age (F=8.4;
p<0.0005) (see Figure 5). Overall in-hospital mortality was 7.0% (95% CI: 6.6-7.4%)
in men and 9.9% (95% CI: 8.6-11.2%) in women (F=21.4; p<0.0005). In all age cat-
egories, mortality in women was than men, but only statistically significant for the
age category 60-69 years (F=7.6; p=0.006). The multiple linear regression analysis
(Table 1) showed age and endovascular repair to be the most important independ-
ent predictors of in-hospital mortality. The year of operation was not statistically sig-
nificant. 
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Figure 4
Number of abdominal aortic aneurysm repairs between 1991 and 2000 related to age and gender.
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2.4. Discussion
This nation-wide study indicates that the introduction of endovascular treatment in
1994 has had an impact on overall in-hospital mortality following intact infrarenal
AAA repair. Although the number of available variables is limited, multivariate
analysis incorporating age, gender, year and type of repair, and hospital size and
type supports this statement by showing that type of repair, age, and gender are
statistically significant predictors of mortality and not the year of operation. Data
were obtained from Prismant, which is a national registry for medical diagnoses
and procedures. Obviously, only a limited number of possible variables and trends
can be analysed from a registry, whereas operative mortality of aortic aneurysm
repair has been demonstrated to correlate with several cardiovascular risk fac-
tors.
5,6
Moreover, this is a descriptive retrospective study and not a randomised
trial. Patients treated endovascularly were entered into this group because of the
aorta anatomy, amongst other reasons not specified, however, not randomly.
Despite these limitations, the impact of endovascular repair seems obvious. 
As has been described earlier, no information was available on pre-operative
risk factors like cardiovascular or pulmonary history and inflammatory or sympto-
matic presentation of the aneurysm. In The Netherlands it is not uncommon for
high-risk patients to be referred for treatment at University Hospitals. However,
apart from two individual years (1995 and 1996), in which the effects were comple-
mentary, hospital type and class did not have a significant impact on in-hospital
mortality in the univariate analysis or in the multivariate analysis. 
Mortality increased with age. The group of patients younger than 50 years
0%
0,05%
0,1%
0,15%
0,2%
0,25%
<50 50-59 60-69 70-79 >79
Male 
Female
Figure 5
Mortality rate in 16,446 intact infrarenal abdominal aortic aneurysm repairs between 1991 and 2000 relat-
ed to age and gender. Bars represent the 95% confidence intervals.
comprises only 129 patients (0.8%). In the subsequent age decades, an increase in
mortality is unmistakable and reflected in both univariate and multivariate analy-
sis. An identical pattern is seen when analysing mortality in the different age
groups for both genders separately (Figure 5). In all age groups, mortality in women
exceeded that in men. Again, this difference was significant in both univariate and
multivariate analysis. 
The results of this study can be used in the management of AAAs to help
answer the question of whether to repair or not to repair, although additional vari-
ables need to be studied. This decision should be the result of balancing the risk of
rupture versus the risk of operative treatment. The risk of rupture increases with the
diameter of the aneurysm. Ledere et al. reported on a group of 198 veterans with
an aortic aneurysm over 5.5 cm that refused or were unfit for elective repair.
1
They
found a 1-year rupture rate of 9.4% for aneurysms of 5.5-5.9 cm that increased to
32.5% for those over 7.0 cm. There is a large variation in reported mortality follow-
ing conventional aortic aneurysm repair. In contrast to selective published series of
major vascular surgical centres, objective mortality rates are reflected in popula-
tion-based series, including multicenter figures of operations performed in all hos-
pitals in a country.
7,8
In a review of publications between 1985 and 1996,
Blankensteijn et al. found a 30-day mortality for elective aortic aneurysm repair of
7.4-8.2%.
7
Moreover, the results of the UK Small Aneurysm Trial showed a signifi-
cant higher mortality (5.8%) than expected in the design of the study (2%).
8
Hypothetically, mortality is reduced by the introduction of endovascular repair.
In the current study, mortality in the group of 15,589 patients who underwent con-
ventional surgery was 7.6% (1191 patients), whereas the overall mortality in the
entire group of 16,446 patients, including endovascularly treated patients, was
7.3% (1207 patients). 
Undoubtedly, some selection bias will be in effect leading to smaller and easi-
er aneurysms having a greater chance of being treated by endovascular means. In
our opinion, however, it is not to this extent that the majority of endovascular
repairs are performed in patients with aneurysms less than 5.5 cm as Collin and
Murie suggest.
9
It is more likely that an opposite selection bias is also in effect by
which older and higher-risk patients, that are unsuitable for conventional repair, are
accepted for an endograft. This would lead to a higher mortality rate in the
endovascular group. This might partially explain the increase in mortality in the
group who underwent endovascular repair in the subsequent years, as the indica-
tions of patients accepted for endovascular treatment became less strict as experi-
ence with the procedure increases. 
For the same reasons of selection bias, the results of this study cannot be used
to promote endovascular repair over conventional repair. The study merely sug-
gests that incorporating an endovascular program can have a positive effect on
population-based mortality of AAA repair. It has to be taken into account that in
this study, in-hospital mortality was analysed. Following discharge after endovascu-
lar AAA repair several problems might still occur, even rupture.
10,11
These factors
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could not be included in this study as they were not available in the registry.
Obviously this limitation may have had a positive impact on the in-hospital mortal-
ity of endovascular repair, although early ruptures are extremely rare, and we are
unaware of such early ruptures in the Netherlands. A further limitation of the regis-
try is that it documents data on non-ruptured AAA repair. Consequently, this group
included intact but symptomatic aneurysms and the subgroup carried a higher
mortality. Still, the overall mortality did decline over a 10-year period in which
endovascular treatment was introduced. Apart from mortality, other issues like
quality of life and cost-effectiveness must be taken into account before the gold
standard of conventional aneurysm surgery can be replaced by endovascular
repair. 
Randomised controlled trials are currently running (the EVAR-trial in the United
Kingdom, the DREAM-trial in the Netherlands and the OVER-trial in the USA).
Results of these trials are eagerly awaited. 
With the limitations of a retrospective analysis of national registry data in mind,
we conclude that trends over a decade seem to indicate that the introduction of
endovascular repair has had a small but significant impact on overall in-hospital
mortality following intact infrarenal AAA repair.
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Abstract
After the introduction of endovascular repair of abdominal aortic aneurysms (AAA),
both benefits and drawbacks of this new technique have been reported. To assess
whether the new technique is an adequate substitute of conventional AAA repair, a
randomised study is due. The DREAM trial is a randomised multicenter trial
enrolling patients eligible for elective treatment of infrarenal AAA's. In this study,
the cost-effectiveness of endovascular aneurysm repair (EVAR) is compared with
that of conventional transabdominal surgery, in patients that are considered suit-
able for both types of treatment. The primary endpoint is combined operative mor-
tality and morbidity. Secondary endpoints and additional assessments include
event free survival, quality of life, length of hospital stay and costs. It is expected
that the DREAM-trial will lead to a safe and controlled introduction of a new tech-
nology. Also, the medical community will obtain valid scientific evidence of the
merits of endovascular AAA repair. Finally, policy makers will be provided with accu-
rate cost-effectiveness data for the Dutch healthcare system. The aim of the pres-
ent paper is to describe the background, methods and design of the DREAM-trial.
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3.1 Introduction 
Based upon population screening programs, the prevalence of an AAA in men over
65 years is estimated to be 5-8%.
1-6
As a result of the ageing of the population and
the improvement of diagnostic modalities the absolute number of individuals with
an AAA increases as well as the proportion in whom its presence is known.
7
Aneurysms commonly remain symptomless until they rupture. The risk of rup-
ture is low but increases exponentially with increasing diameter of the aneurysm.
8,9
In case of a  rupture of an AAA mortality is high (85%).
10,11
Prophylactic surgery, i.e.,
elective abdominal aneurysm repair has a 30-day mortality rate of about 7%.
12,13
Based upon the results of the UK Small Aneurysm Trial it appears that ultrasono-
graphic surveillance until the diameter of the aneurysms exceeds 5.5 cm, or grows
more than 1.0 cm per year or until the aneurysm becomes tender is a safe alterna-
tive.
14
Since the introduction of endovascular repair of AAA (EVAR) in 1991 by Parodi,
many endovascular devices in various configurations have been developed.
Because the endovascular technique is less invasive, a significant decrease in short-
term mortality and morbidity was expected and has indeed been demonstrated.
15,16
Also, EVAR is expected to result in faster patient recovery and in a shorter hospital
stay. This may also lead to a significant reduction in costs associated with AAA
repair as compared to the conventional procedure. However, EVAR is an expensive
procedure and certainly more costly than open repair. Several cost effectiveness
studies have shown EVAR to be more expensive, though still cost effective.
17
The lat-
ter should be interpreted as though the extra costs are considered worthwhile in
terms of improved outcome.
18
However, presently long-term outcomes after EVAR are unknown and as the
mid-term results after EVAR become available, concerns about the complication
rates and long term durability of endovascular prostheses have been raised.
19-22
It is still not known whether EVAR is equivalent to conventional repair, better or
possibly even worse. The only evidence available at this moment is derived from
observational studies based on selected patient populations. This is likely to have
resulted in biased results. For instance, if only patients with a relatively simple
aneurysm were included, the success of EVAR could have been overestimated. On
the other hand, in the initial stage of EVAR only high risk patients were treated
endovascularly, which may have affected the outcome of EVAR adversely.
23
These
issues cannot be solved adequately until a comparative study with random alloca-
tion to conventional or endovascular repair is conducted. The Dutch Randomised
Endovascular Aneurysm Management (DREAM) trial is such a randomised multi-
center study enrolling patients offered an elective treatment of an infrarenal
abdominal aortic aneurysm. In this paper the design, methods and aims of the
DREAM-trial are described.
3.2 Study design
Grant Giving Body
The Dutch Health Insurance Council funded the current study. It was not until sev-
eral hurdles were taken that evaluating EVAR could be started. Many consider
EVAR as an experimental intervention. The latter was the principal reason for rejec-
tion of the study in several consecutive grant application rounds. Also, the variety
of the devices available on the market and be allowed for application in the study
was previously considered a methodological flaw, because of a suspected diluting
effect. However, the aim of this study is to compare two strategies to treat an AAA,
i.e. the conventional versus the endovascular repair, rather than one particular
device versus another. Accordingly, the study should allow using all devices
approved and available on the market, as well as having various surgeons perform
both the EVAR as the conventional procedure.
Another criticism raised was that EVAR should be considered a 'moving' tech-
nology. Old devices are improved and new devices are released, which could mean
that results may be out of date by the time the study is published. Although we
recognise this is an important fact, waiting for the developments to end is impossi-
ble, because of the ever-continuing technological advances and the technique thus
is introduced without any valid and solid evaluation. Note also that this phenome-
non is inherent to any development and science, in particular medicine, and can
only be addressed using valid statistical methods. 
Organisational Structure
A surgeon and a radiologist of each center partake in the trial steering committee
(TSC). The TSC has final responsibility for the conduct and reporting of the trial. The
site and device selection committee (SDSC) ballots potential participating centers
and physicians, and oversees the application of the guidelines issued by the
Endovascular Safety Committee of the Dutch Society for Vascular Surgery and the
Dutch Society for Radiology. A data monitoring and ethics committee (DMEC) is
installed to ensure the proper conduct of the trial. This committee assesses the ethi-
cal aspects and monitors the safety aspects of the trial, based upon reports of the
TSC. The University Medical Center in Utrecht is the co-ordinating center of the
DREAM-trial.
Participating centers and physicians
The study was approved by the Institutional Review Board. The participating cen-
ters and physicians are required to comply with the guidelines for endovascular
AAA repair issued by the Endovascular Safety Committee of the Dutch Society for
Vascular Surgery and the Dutch Society for Radiology. Specifically, surgeons and
radiologists are required to co-operate in the trial. They should have passed their
'learning curve' in endovascular AAA repair prior to full participation. This means
that they are required to have performed at least 20 endovascular procedures. The
scrub nurses and radiology technicians have to be trained specifically for EVAR.
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Physicians not yet meeting the criteria for participation have the opportunity to par-
ticipate by doing the endovascular procedure under supervision of an experienced
colleague.
Furthermore, the participating centers are required to have a yearly volume of
at least 30 conventional AAA repairs and 50 endovascular procedures, such as PTA
and stent placement.
A subgroup of participating centers performs conventional repair only. These
centers refer their patients to an endovascular center. In case of allocation to con-
ventional treatment, the patient is referred back to the initial center. This trial
design preserves normal referral patterns as far as possible. Thus, hospitals not yet
performing EVAR or limited numbers of conventional AAA treatment, but otherwise
meeting the criteria for participation, have the option to participate and treat their
own patients allocated to conventional treatment. Another reason for choosing this
design is that co-operation between centers is stimulated paving the way for refer-
ral of patients and subsequent inclusion. 
Devices
Requirements for devices to be included in the DREAM trial are consistent with the
European CE-mark and Preliminary Market Approval (PMA) or Investigational
Device Exemption (IDE) of the United States Food and Drug Administration (FDA).
With respect to EVAR, any configuration is allowed including tube, bifurcated,
and mono-iliac devices, extension cuffs, and suprarenal fixation, such to the discre-
tion of the surgeon performing the procedure. Preservation of at least one hypogas-
tric artery must be planned.
Eligibility and exclusion criteria
All patients with an AAA eligible for EVAR as well as conventional open repair are
considered for participation in the DREAM trial. Patients have to meet the entry cri-
teria, which are listed in table 1.
Patient recruitment, Informed Consent and registration
In the participating centers all elective patients with an AAA of at least 5.0 cm are
evaluated for both treatments. The results of the UK small aneurysm trial have
shown that there is no benefit for surgical treatment until the aneurysm has
reached a diameter of 5.5 cm.
14   
In this study the line for inclusion was drawn at
5.0 cm and not at 5.5 cm. This lower limit was chosen because there is often a
variation between the measurements and the work-up for the intervention will also
take some time. 
To standardise the information given to the patient, prior to physician contact
patients receive a general information brochure explaining the treatment options
for an AAA and announcing the DREAM-trial. The attending physician informs a
patient who meets the entry criteria. Patients willing to participate in the study are
included after signing an informed consent form. The surgeon then contacts the
randomisation center by telephone and the result of the randomisation is given
immediately. Because it is expected many variables will be specific to the participa-
ting centers (i.e. type of device, experience of the team etc.), randomisation is strati-
fied by center. 
Finally, the grant giving body also demanded an anonymous registration of all
patients being treated for an AAA in the participating centers to get an overview
of the aneurysm surgery in the Netherlands. On a general registration form the
treatment allocated is registered. In case of exclusion for the trial the reason for
exclusion is also mentioned.
Sample size
The required sample size was estimated to amount to 400 patients (200 in each
arm of the trial). This estimate is based on the expectation of reducing the com-
bined operative mortality and morbidity from 20% in open to 10% in endovascular
surgery. To be able to detect this relative reduction in operative mortality and mor-
bidity of 50% with a statistical power of 80% (b = 0,2) and a = 5%, 196 patients
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Table 1
In- and exclusion criteria
Inclusion Criteria
• Non-symptomatic infrarenal AAA, for which an intervention is indicated
• Adequate infrarenal neck
• Other aorto-iliac anatomical configuration suitable for EVAR according to the criteria of the device
used
• Patient having a life expectation of at least two years and cleared for transabdominal intervervention
• Signed informed consent
Exclusion Criteria
• Ruptured AAA or symptomatic AAA, which requires emergency surgery
• Maximum aneurysm diameter <5.0 cm
• Juxtarenal or suprarenal AAA
• Inflammatory AAA (more than wall thickening)
• Infrarenal neck unsuitable for endovascular fixation or aorto-iliac configuration otherwise unsuitable
for EVAR
• Bilateral retroperitoneal incision required for EVAR
• Inflammatory AAA (more than wall thickening)
• Sacrifice of both hypogastric arteries required
• Anatomical variations, i.e. horseshoe-kidney, arteries requiring reimplantation  (accessory renal
arteries or indispensable IMA)
• Patient unsuitable for laparotomy (i.e. multiple abdominal surgical interventions)
• Administration of contrast agent not possible: proved, severe systemic reaction to contrast agent
• Active infection present
• Transplantation patients
• Limited life expectation due to illness other illness (< 2 years)
• Non-iatrogenic bleeding diathesis
• Connective tissue disease
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are required in each arm of the trial. Taking into account a 10% of the patients
refusing participation, almost 450 eligible patients are needed.
The yearly volume of elective AAA repair in the participating centers is esti-
mated between 500 and 800. Considering some differences in inclusion percent-
ages for the endovascular treatment (30-50%) between the centers based on the
use of different devices, 400 patients are expected to be randomised within 3 years.
3.3 Outcome measures
Combined operative mortality and morbidity
The primary outcome for the DREAM trial is the combined peri-operative mortality
and morbidity. All moderate and severe complications are independently assessed
at 30 days and combined in one comprehensive outcome. Complications are
defined conform the SVS/AAVS reporting standards, dividing the complications into
two groups, 'remote/systemic' and 'local/vascular'.
24,25
Quality of life
Quality of life (QoL) is assessed throughout this trial with the Medical Outcomes
Short Form 36 (SF-36) questionnaire, the EQ5D and a short questionnaire about
sexual function. The SF-36 has been widely used to measure the impact of many dif-
ferent health interventions and the form is scored on eight dimensions, which
encompass general heath, physical function, vitality, bodily pain, social function and
mental health.
26
The results obtained by means of the EQ5D will be used to esti-
mate survival time adjusted for QoL.
QoL during follow up will be compared to the preoperative assessment using
non-parametric tests for paired samples.
Cost effectiveness
The effectiveness of the endovascular AAA treatment versus that of the conven-
tional repair will be determined in terms of operative mortality, early and late com-
plications, overall mortality and quality of life. The latter also comprises an index
measure, i.e., utility, of overall quality of life that can be used to adjust survival time.
Short-term results encompass outcome measures reported within a 30 day- and
6-month time frame. Mid-term results refer to outcome measures up to two years
after EVAR and long-term results include all outcomes beyond two years.
24
The long-
term effectiveness of the endovascular prosthesis is not known yet. Because follow-
up in this trial is limited it will not be possible to obtain long-term results of the
effectiveness of EVAR within the study. To approximate these results an arithmetic
model, i.e., a Markov Monte Carlo simulation model, based on results of earlier
studies will be used.
In parallel with the clinical study the costs of the operation will be determined
for both trial arms, including a detailed assessment of the costs of staffing, investi-
gations, drugs and overheads. In addition the indirect costs due to losses in produc-
tion of paid and unpaid labour will be estimated. To estimate the costs associated
with long-term outcomes the above-mentioned model will again be used. Finally,
the model will also be used to compare the balance between costs and effects
across the arms of the trial in terms of incremental costs per life year gained and
per quality adjusted life year (QALY) gained. 
Continuous sequential analysis of safety
EVAR is a evolving technique and in recent history we have witnessed several
devices being withdrawn from the market because of some technical failures occur-
ring.
27,28
Failing devices obviously pose a risk to patients having undergone EVAR.
The actual hazard, the extent and type of complications associated however are
unknown at present. Conversely, the conventional open repair has a long track
record with known advantages and disadvantages.
29
It would appear that conduct-
ing a study such as the DREAM trial, which uses an experimental device, is accept-
able only if the safety of the participants is guarded. Therefore, if at any time dur-
ing follow-up a primary endpoint, i.e., serious morbidity or mortality, an infection of
the prosthesis or AAA rupture occurs an independent blinded (survival) analysis will
be carried out to compare the incidence of the above outcomes across the arms of
the trial. This so-called continuous sequential analysis will enable the TSC to take
adequate action as soon as the data show a considerable difference (OR <0.5 or
OR >2) in incident adverse outcomes. The safety of potential participants not yet
randomised is thus safeguarded.
Final analysis
One month after inclusion of the last patient, the analysis of the operative mortal-
ity and morbidity data will be performed. One year after this last inclusion the
majority of patients will have had a follow up of 18-30 months. Based on these
results a prediction will be made about the effectiveness of EVAR in prevention of
further expansion or rupture of the aneurysm. 
3.4 Conclusion
The DREAM-trial will hopefully lead to safe and controlled introduction of a new
technology and will provide the medical community with valid scientific evidence on
the merits of endovascular AAA repair. Also, policy makers will be provided with
information on the cost-effectiveness of this new therapy for the Dutch Healthcare
setting.
In February 2001 the first patient has been included in the trial, so the first
results of the DREAM-trial are anticipated in early 2004.
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Abstract
In many randomised trials, an interim analysis based on the primary endpoint is
foreseen, for example halfway during patient inclusion. In surgical trials interim
analyses are typically based on primary endpoints such as 30-day mortality or mor-
bidity. However, specific disorders or procedure-related complications may occur
any time. Accordingly, continuous monitoring of safety, evoking a blinded interim
analysis every time a serious event occurs, should be considered. This would enable
adequate action to be taken as soon as the data reveal a relevant and significant
difference in incident adverse events. A clinically relevant difference in adverse
events is thus detected in a timely fashion, which will ensure the safety of potential
participants not yet randomised. The concept of continuous safety monitoring is
described in the context of the DREAM trial, a randomised multicentre surgical
trial.
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4.1 Introduction
Randomised clinical trials must be monitored carefully during their conduct.
Common practice is to install an independent data monitoring and ethics commit-
tee (DMEC), responsible for protecting ethical and safety interests of current and
future patients. Early evidence of clear treatment benefit or harm should prompt an
immediate halt to the study to prevent further patients from being randomised and
potential exposure to an inferior treatment. For this purpose, generally, one or more
interim analyses are foreseen during the course of the trial. In surgical trials, such
analyses are typically based on the primary endpoint of the study and are frequent-
ly limited to 30-day mortality and/or morbidity. As a result complications and seri-
ous adverse events occurring after the first 30 postoperative days usually are not
incorporated in the interim analysis. It would appear, however, that an immediate
alert should be triggered by important adverse events regardless of their timing.
Continuous sequential safety monitoring is a method that enables timely action
based on accumulating evidence of relevant differences in adverse events.
1
To illus-
trate the principles and to draw attention to the issue of patient safety we describe
the methods and the pros and cons of continuous sequential safety monitoring,
within the context of a randomised multicentre surgical trial.
4.2 Study design
The Dutch Randomised Endovascular Aneurysm Management (DREAM) trial aimed
to assess the potential benefits of minimally invasive endovascular repair (EVAR) of
abdominal aortic aneurysms (AAA) as compared to conventional open repair (OR).
The primary endpoint chosen for the DREAM trial was 30-day mortality or moder-
ate or severe morbidity.
2
The study design has been described in detail elsewhere.
3
For the power calculation of the DREAM trial a reduction of the primary endpoint
of 50% was assumed for the EVAR-group (10%) compared to the OR-group (20%).
A two-sided comparison with a statistical power of 80% and a significance level
a=5% called for at least 196 patients to be included in each trial arm.
Theoretically, EVAR was expected advantageous by avoiding an extensive and
invasive open procedure with potential serious complications.
4
However, EVAR is an
evolving technique and in recent history several endovascular devices have been
withdrawn from the market because of technical failures.
5-7
Failing devices obvious-
ly would pose a risk to patients who underwent EVAR. Also specific complications
or drawbacks of EVAR require an extensive follow-up.
8
Apparently, the actual haz-
ard, the extent and the types of complications associated with EVAR are poorly
defined at present, whereas, OR has a long track record with known benefits and
drawbacks.
9,10
This resulted in the notion that safety monitoring of the DREAM trial
should not be limited to the primary endpoint of 30-day mortality and morbidity,
and in fact would require a time-to-event analysis. To achieve this goal continuous
sequential survival analysis was considered the method of choice. To detect a sta-
tistically significant difference in adverse events of 10%, which corresponds to a
hazard ratio (HR) smaller than 0.47 or larger than 2.12, by means of a continuous
sequential survival analysis would require at most 62 adverse outcomes in approx-
imately 413 patients.
11
Moreover, if indeed a 10% difference would exist, it should
on average be detected after 42 adverse events in about 277 included patients.
Thus, adding a continuous sequential safety monitoring design to the trial does not
result in a substantial increase in the total number of patients to be included. 
4.3 Continuous sequential safety monitoring: procedure
Sequential safety monitoring can be viewed as a specific form of interim analyses,
comprising all relevant adverse events. If at any time during follow-up an adverse
event occurs an independent (blinded) interim analysis is conducted using survival
analysis. In other words the cumulative incidences of adverse events across the trial
arms are compared repeatedly. The insights thus obtained enable trial steering
committees to take adequate action as soon as the data reveal a considerable
imbalance in adverse events between the trial arms. This ensures the safety of
potential participants not yet randomised. The major difference between interim
analyses and sequential safety monitoring is that contrary to sequential monitoring
the number of patients to be included is fixed with interim analyses, consequently
it is not possible to stop the trial earlier. Moreover, if you don't want to enlarge the
risk of making a type I error, a needs to be adjusted performing interim analyses.
Data-management should be organized in such a way that a data set required
for an analysis of adverse events is generated the moment a predefined adverse
event is reported. Note that complete data on every patient enrolled are not
required; type and timing of adverse events and the trial arm (and stratification fac-
tors when appropriate) suffice. In the DREAM trial, an independent statistician con-
ducted interim analyses every time serious morbidity or mortality, or an infection of
the prosthesis, or AAA rupture occurred. The incidence of these outcomes across
the arms of the trial was thus successively compared. The hazard ratios mentioned
above (smaller than 0.47 or larger than 2.12) were chosen as safety thresholds. A
result outside this range would have to be communicated immediately to the safe-
ty monitoring committee. Upon receiving and weighing this information against
other available information, the safety monitoring committee was to advise the trial
steering committee on the appropriate action to be taken. If no imbalance in
adverse events appeared the trial was to be continued until the planned number of
413 patients was included.
4.4 Continuous sequential safety monitoring: simulation examples
using the DREAM trial setup
Simulations of the trial were generated with the computer program Planning and
Evaluation of Sequential Trials (PEST).
12
Based on preset parameters, such as the
anticipated rate of events per arm, the hazard ratio, the significance level and the
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power, the program generates events occurring during a hypothetical trial realisa-
tion (simulation). Every time an event occurs, two quantities, one representing the
thus far accumulated information (V) and one representing the effect size (Z), are
calculated based on the cumulative data. For survival data V approximately corre-
sponds with a quarter of the total number of events, whereas Z corresponds with
the observed number of events in the control group (i.e. OR in the DREAM trial)
minus the expected number of events under the assumption that the treatments are
equivalent in terms of their survival probabilities.
13
Positive values of Z indicate a
relative excess of undesirable events in the control group (OR in the DREAM trial)
and thus superiority of the experimental treatment (EVAR in the DREAM trial). (Note
that Z2/V corresponds with the log rank test statistic for comparison of two groups
with a survival outcome variable.) 
Z and V can be depicted in a (Z,V)-plot, with V on the horizontal axis and Z on
the vertical axis. As the simulated enrollment is achieved and virtual trial time pass-
es, subsequent events result in (Z,V)-points which are plotted in the (Z,V)-frame
(Figures 1 and 2). Upper and lower (sloped) boundaries are calculated and plotted
depending on the significance level, the power and the hypothesized effect size (in
terms of the logarithm of the hazard ratio). The inner curved boundaries are a con-
tinuity correction for the outer straight boundaries. The vertical boundary on the
right is determined by the maximum number of events in a planned maximum num-
ber of patients to be included (in the DREAM trial 62 successive events in 413
patients).
10
Figure 1
Results from a simulation study under the alternative hypothesis "cumulative survival probability at 1 month
is 0.8 for OR and 0.9 for EVAR i.e. a hazard ratio of 0.47".
A total of 231 hypothetical patients were included with 32 events, 23 in the OR-group and 9 in the EVAR-
group.
8
6
4
2
0
-2
-4
-6
-8
-10
Z
2 4 6 8 10 12 14 16
V
If the plot of consecutive (Z,V)-points, the so-called 'sample path', crosses the
upper or the lower boundary, the null hypothesis of treatment equivalence is reject-
ed. However, if the successive (Z,V)-points stay within the two boundaries and the
vertical boundary is eventually crossed, this implies that the null hypothesis can not
be rejected, or, no significant difference in adverse events between treatments is
found. 
A simulation study geared to reproduce the alternative hypothesis of a cumula-
tive event free survival probability at 1 month of 0.8 for OR and 0.9 for EVAR, i.e.
a hazard ratio of 0.47, was run. This yielded a total number of 231 hypothetical
patients with 32 events (23 in the OR group versus 9 in the EVAR group) before the
upper boundary was crossed, showing EVAR to be superior to OR (Figure 1).
Conversely, performing a simulation study for the null hypothesis of the DREAM
trial, with 30 day cumulative event free survival probabilities of 0.8 for both EVAR
and OR, i.e. a hazard ratio of 1.0, yielded a total number of 330 hypothetical
patients included with 62 events (33 in the OR-group and 29 in the EVAR-group).
This simulation clearly indicated no difference between the two treatments and,
ultimately, the vertical boundary was crossed (Figure 2). 
4.5 Discussion
In clinical trials, interim analyses are usually performed for ethical and sometimes
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Figure 2
Results from a simulation study under the null hypothesis "cumulative survival probability at 1 month is 0.8
for both EVAR and OR, i.e. a hazard ratio of 1.0".
A total of 330 hypothetical patients were included with 62 events, 33 in the OR-group and 29 in the EVAR-
group.
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economical reasons. Ultimately, investigators are seeking for a legitimate possibili-
ty to stop a trial early, and, clearly, if the data show a relevant difference between
the trial arms this would be a good reason to stop enrollment. For pragmatic rea-
sons the number of interim analyses is usually low (one to five). Note, however, that
with each subsequent statistical test performed the risk of making a type I error
exists. One is spending the overall a bit by bit with each subsequent interim analy-
sis. This may be considered the 'price' of interim analyses. In most trials 0.05 is cho-
sen for the overall a. Thus, with repeated testing of cumulative data and no adjust-
ment, the overall type I error, i.e. a false positive result, can accumulate. Each inter-
im analysis should be performed with a smaller nominal a, to guarantee the over-
all a for the study remaining 0.05. Therefore Pocock and O'Brien and Fleming, sug-
gested that the number of interim analyses foreseen should be mentioned in the
study protocol and a nominal   per interim analysis used.
14,15
The major disadvan-
tage of this type of analysis is that the number of interim analyses is fixed. Every
interim analysis will be performed after inclusion of a fixed number of patients or
events in the study. However in most studies the inclusion rate varies, as does the
occurrence of events. This factual problem calls for flexible solutions. For instance,
to evaluate the progression of a trial regularly a formal a-spending-function may
be used.
16
With this method the number and time points of analyses does not need
to be determined a priori. A far more flexible way of monitoring described by
Whitehead is based on boundaries set at the design phase of the trial. These
boundaries guarantee the specified overall a and power 1-b for every moment the
boundaries are crossed and thus justify early stopping of the study.
13
The advan-
tage of this method is that the number of analyses is not limited. Accordingly, every
time during the trial an event occurs a blinded analysis can be carried out, and a
decision whether the data show a statistically significant difference is reached in
pace with the events occurring. 
For the DREAM trial a so-called restricted procedure was chosen. The bound-
aries chosen in the DREAM trial were based on the assumption that a hazard ratio
of smaller than 0.47 or larger than 2.12 detected with a two-sided a=0.05 and a
power 1-b=0.80 would be relevant. This meant that if in the EVAR group serious
adverse events had appeared two times more likely or two times less likely than in
the conventional group, the DMEC of the DREAM trial had to be informed and
could have advised the study to be stopped. A hazard ratio smaller than 0.67 or
larger than 1.5 was considered as too conservative. The number of patients need-
ed to show such a difference between the two groups would be too high and there-
fore the trial would take too long. On the other hand, a hazard ratio of smaller than
0.33 or larger than 3 was considered insensitive. 
Bolland and Whitehead describe sequential safety monitoring as a special
example of interim analyses.
1,13
A disadvantage of Bolland and Whitehead's
approach is that it, at present, only allows one-sided testing. This method is there-
fore only applicable in studies assuming the experimental method being as good
as or worse than the standard treatment. Another disadvantage of this method is
that it requires dichotomous data, because the computer program PEST is not yet
fit for survival data.
An important issue to recognize is that only endpoints which occur relatively
shortly after inclusion, i.e., those occurring during the trial inclusion period, are suit-
able for sequential monitoring for the obvious reason that events occurring after
reaching the intended maximum enrollment cannot lead to a reduction of the num-
ber of randomised patients. This does not mean that the method has no use at all
for outcomes occurring at a later phase. Specifically, continuous monitoring of long-
term complications may have implications for the required follow-up protocol.
Another issue important to recognize, particularly in surgical trials is the notion
of a 'learning curve'. Obviously, any type of interim analysis performed when the
experimental procedure is maturing may lead to unjust stopping of a trial. 
4.6 Conclusion
Performing continuous sequential safety monitoring enables trial investigators to
stop the trial the moment the cumulative data show a significant imbalance in inci-
dence of adverse events, while guaranteeing a preset type I error. The safety of
patients not yet randomised can thus be safeguarded.
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Abstract
Background
Although the initial results of endovascular repair of abdominal aortic aneurysms
were promising, current evidence from controlled studies does not convincingly
show a reduction in 30-day mortality relative to that achieved with open repair. 
Methods
We conducted a multicenter, randomised trial comparing open repair with
endovascular repair in 345 patients who had received a diagnosis of abdominal
aortic aneurysm of at least 5 cm in diameter and who were considered suitable
candidates for both techniques. The outcome events analyzed were operative (30-
day) mortality and two composite end points of operative mortality and severe com-
plications and operative mortality and moderate or severe complications. 
Results
The operative mortality rate was 4.6 percent in the open-repair group (8 of 174
patients; 95 percent confidence interval, 2.0 to 8.9 percent) and 1.2 percent in the
endovascular-repair group (2 of 171 patients; 95 percent confidence interval, 0.1 to
4.2 percent), resulting in a risk ratio of 3.9 (95 percent confidence interval, 0.9 to
32.9). The combined rate of operative mortality and severe complications was 9.8
percent in the open-repair group (17 of 174 patients; 95 percent confidence inter-
val, 5.8 to 15.2 percent) and 4.7 percent in the endovascular-repair group (8 of 171
patients; 95 percent confidence interval, 2.0 to 9.0 percent), resulting in a risk ratio
of 2.1 (95 percent confidence interval, 0.9 to 5.4). 
Conclusions
On the basis of the overall results of this trial, endovascular repair is preferable to
open repair in patients who have an abdominal aortic aneurysm that is at least 5
cm in diameter. Long-term follow-up is needed to determine whether this advan-
tage is sustained.
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5.1 Introduction
Elective surgical repair is indicated in patients with a large abdominal aortic
aneurysm. The threshold for surgery is still a subject of debate but varies between
5.0 and 5.5 cm in diameter.
1-4
Endovascular repair, pioneered by Parodi and
Volodos in the early 1990s, is a less invasive alternative to conventional open
repair.
5,6
Endovascular repair usually involves two small incisions made in the groin
to expose the femoral arteries. With the use of guidewires, catheters, and specially
designed introducer systems, a so-called endograft is assembled inside the ab-
dominal aortic aneurysm under fluoroscopic guidance, thus excluding the
aneurysm sac without opening the abdomen. 
From its inception, endovascular repair has been used in patients for whom
open repair poses a high risk. At the same time, patients with relatively few  coex-
isting conditions are more likely to meet the anatomical criteria for endovascular
repair, including the presence of a suitable infrarenal aortic neck and absence of
severe aortoiliac tortuosity and calcification in the arterial wall.
7
These factors lead
to selection in retrospective analyses and uncontrolled prospective evaluations and
make an unbiased assessment of the benefits and risks of the two techniques
problematic.
8-15 
Although the initial results of endovascular repair were promising and the less
invasive nature of the procedure is appealing to many patients and physicians, evi-
dence is needed that demonstrates the superiority of this approach over open
repair, as are conclusive data on cost-effectiveness.
16-18
We conducted a multicenter, randomised trial - the Dutch Randomised
Endovascular Aneurysm Management (DREAM) trial - to compare operative mor-
tality and complications and other outcome events after elective open repair and
endovascular repair.
5.2 Methods
Study design and patients
The design and methods of the trial have been described in detail elsewhere.
19
In
brief, patients referred to surgery clinics at 24 centers in the Netherlands and 4
centers in Belgium who had received a diagnosis of an abdominal aortic aneurysm
of at least 5 cm in diameter and who were considered suitable candidates for both
techniques were randomly assigned to undergo open or endovascular repair, after
giving written informed consent. A patient's suitability for endovascular repair was
primarily determined by means of endograft-dependent anatomical criteria. A
patient's suitability for open repair was determined by an internist or cardiologist.
Patients who needed to undergo emergency aneurysm repair were excluded from
the study, as were patients with inflammatory aneurysms, anatomical variations,
connective-tissue disease, a history of organ transplantations, or a life expectancy
of less than two years. The study was performed according to the principles of the
Declaration of Helsinki, and the institutional review board of each participating
hospital approved the protocol. Randomisation was carried out centrally by means
of a computer-generated permuted-block sequence and stratified according to
study center in blocks of four patients. 
An independent data-monitoring and ethics committee decided whether to con-
tinue the trial on the basis of a single interim analysis of the 30-day end points per-
formed after half the required number of patients had been enrolled. In addition,
sequential monitoring was used to monitor the incidence of death from all causes
and all moderate and severe complications (not just those at 30 days) in order to
safeguard against divergent outcomes beyond the perioperative period, for
instance, as a result of endograft failure.
20
Surgical techniques
All repairs were carried out by surgical teams that had performed at least five
endovascular procedures. Surgical teams that had performed less than 20 proce-
dures were required to have an experienced proctor assist them during the proce-
dure. Only endovascular devices that had been approved by the U.S. Food and
Drug Administration (FDA) or that had an Investigational Device Exemption or
Conformité Européen mark were allowed in the study. Endovascular repair typical-
ly involves small incisions in the groin to expose both femoral arteries, although
some surgeons prefer a total percutaneous approach. The endograft is composed
of fabric and metal stents and comes loaded in a specially designed delivery sys-
tem. Under fluoroscopic guidance, this introducer system is fed through the iliac
arteries by means of catheters and guidewires until the endograft is positioned cor-
rectly at the top and bottom of the aneurysmal segment of the aorta. Removal of
the introducer system allows barbs or other fixing devices to attach to the aortic
wall and hold the graft firmly in place, excluding blood flow from the aneurysm sac
and removing pressure from the aneurysmal wall. The exposure and aneurysm-
repair technique used for open repair was at the surgeon's discretion.
Endpoints
Complications were classified and graded according to the reporting standards of
the Ad Hoc Committee for Standardized Reporting Practices in Vascular Surgery of
the Society for Vascular Surgery/International Society for Cardiovascular
Surgery.
21;22
Three classes of complications (systemic, local-nonvascular, and local-
vascular or implant-related) and three grades of severity (mild, moderate, and
severe) were used. Mild complications were not considered in this analysis.
An outcome adjudication committee, consisting of five vascular surgeons,
assessed the class and severity of each complication in a blinded fashion and inde-
pendently from each other. Disagreements were resolved in a plenary consensus
meeting. The primary end point was a composite of operative mortality and mod-
erate or severe complications. Operative complications were defined as those that
occurred within 30 days after surgery or more than 30 days after surgery but dur-
ing the same admission (in-hospital mortality and complications). Other outcome
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events analyzed were operative mortality and the combination of operative morta-
lity and severe complications.
Statistical analysis
The trial was designed to have 80 percent power to show a reduction of 50 percent
in the primary end point at the two-sided 5 percent level with endovascular repair,
as compared with open repair. The incidence of the primary end point in the open-
repair group was expected to be 20 percent. Four hundred patients were required. 
All analyses were based on all randomised patients who underwent aneurysm
repair. Patients were classified according to the original randomised allocation in
178
assigned to open repair
Figure 1
Randomisation, treatment, and analysis of outcome
173
assigned to endovascular repair
174
for analysis as randomised
171
for analysis as randomised
4 did not undergo aneurysm repair
3 refused
1 died
2 did not undergo aneurysm repair
1 refused
1 died
170
open repairs started
175
endovascular repairs started
173
completed open repairs
171
completed endovascular repairs
5 underwent
endovascular repair
1 underwent
open repair
3 conversions
to open repair
1 procedure aborted
(cross-over)
351
patients randomised
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Table 1
Baseline Characteristics of the Patients and Aneurysms, According to Treatment Group.*
Open Endovascular p-value
Repair Repair
Characteristic (N=174) (N=171)
Age –yr 69.5±6.8 70.7±6.6 0.11
Male sex –no. (%) 157 (90) 159 (93) 0.44
SVS/ISCVS-risk factor score (% moderate or severe)†
Diabetes Mellitus 9.8 9.9 0.97
Tobacco Use 54.0 64.9 0.07
Hypertension 54.0 57.9 0.92
Hyperlipidemia 53.6 47.0 0.22
Carotid Disease 15.1 13.5 0.71
Cardiac Disease 46.6 40.9 0.30
Renal Disease 7.5 7.6 0.98
Pulmonary Disease 17.8 27.5 0.04
Sum of SVS/ISCVS risk factor scores 4.4±2.5 4.4±2.5 0.70
FEV1 –(L/sec) 
‡ 2.6±0.7 2.5±0.7 0.24
Body Mass Index 26.6±4.1 26.2±3.4 0.42
ASA class –no. (%) §
I healthy status 44 (25) 37 (22) 0.45
II mild systemic disease 106 (61) 119 (70) 0.09
III sever systemic disease 24 (14) 14 (8) 0.12
Previous abdominal surgery –no. (%) 56 (32) 43 (25) 0.15
Maximum diameter –mm (Mean±SD) 60.0±8.5 60.6±9.0 0.68
Median (Interquartile Range) 58 (54-65) 58 (55-65)
Aneurysm morphology class (Eurostar) –no. (%) ¥
A: confined to aorta, distal aortic neck available 20 (12) 12 (7) 0.15
B: involves aortic bifurcation, normal iliac arteries 101 (58) 114 (67) 0.12
C: involves both proximal common iliac arteries 20 (12) 16 (9) 0.30
D: extends into one iliac bifurcation 15 (9) 14 (8) 0.90
E: extends into both iliac bifurcations 18 (10) 15 (9) 0.62
Cylindrical shape of infrarenal aortic neck –no. (%) 127 (73) 107 (63) 0.05
Unfavorable features of infrarenal aortic neck –no. (%) †† 74 (43) 92 (54) 0.05
Iliac calcification <25% of the iliac segment –no. (%) 125 (74) 118 (69) 0.40
Unfavorable features of iliac arteries –no. (%) ‡‡ 51 (30) 53 (31) 0.81
* Plus-minus values are means±SD.
† Society for Vascular Surgery / International Society for Cardiovascular Surgery risk factor score
(0=none; 1=mild; 2=moderate; 3=severe).
21
‡ FEV1 denotes Forced Expiratory Volume in 1 sec (L/sec).
§ American Society of Anesthesiologists (ASA).
¥ Eurostar classification of aneurysm morphology.
23
†† Unfavorable neck features: reverse tapered;
diameter>28mm; angulated>30°; length<15mm; mural thrombus>2mm; irregular wall or bulge.
‡‡ Unfavorable iliac features: angulation>90°; diameter>18mm; diameter <6mm or >50% stenosis.
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all analyses. The risk of a complication after open repair was compared with that
after endovascular repair, and the results are presented as risk ratios and exact 95
percent confidence intervals, derived with the use of StatXact software (version 6.1,
Cytel Software). Means (±SD) together with medians and interquartile ranges were
used to describe continuous variables. Frequencies and exact 95 percent confi-
dence intervals were calculated for categorical variables. Differences between
treatment groups were evaluated with the use of the Mann-Whitney U test for con-
tinuous variables or Fisher's exact test for proportions. All reported P values are two-
sided and are not adjusted for multiple testing. 
The study protocol specified that recruitment would end by September 2003,
with the enrollment of 400 patients, and that the study would be completed in
January 2004. After negotiations with the sponsor of the study (the Health
Insurance Council of the Netherlands) about a possible extension, three extra
months were allowed, resulting in an eventual enrollment that was 12 percent
lower than expected. 
The corresponding author had full responsibility for the conduct of the trial, had
full access to all the data, and controlled the decision to publish. The sponsor of the
study had no role in the study design.
5.3 Results
Characteristics of the patients and treatment assignments
Between November 2000 and December 2003, 351 patients were randomly
assigned to undergo either open repair or endovascular repair (Figure 1). Six
patients did not undergo aneurysm repair after randomisation: four declined treat-
ment (three assigned to open repair and one to endovascular repair), one died from
a ruptured abdominal aortic aneurysm before undergoing open repair, and one
died from pneumonia before undergoing endovascular repair. The remaining 345
patients composed the treatment groups: 174 patients in the open-repair group
and 171 in the endovascular-repair group. 
The baseline characteristics of the patients and aneurysms are shown in Table
1. Demographic characteristics, coexisting conditions, cardiovascular risk profiles,
the distribution of American Society of Anesthesiologists classifications, and the
characteristics of the aneurysm were similar in the two groups.
There were six crossovers: five patients who were randomly assigned to under-
go open repair underwent endovascular repair, and one patient assigned to
endovascular repair underwent open repair. Overall, in 96.6 percent of patients
(339 of 351), the operation was started according to the randomised assignment.
The median interval between randomisation and surgery was 39 days in both the
open-repair group (range, 4 to 260) and the endovascular-repair group (range, 1 to
183; P=0.76). 
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Table 2
Characteristics of the Aneurysm Repair Procedures, According to Treatment Group.*
Open Endovascular
Repair Repair
Characteristic (N=174) (N=171)
Type of anesthesia –no. (%)
General 120 (69) 89 (52)
General and regional 51 (29) 5 (3)
Regional 2 (1) © 68 (40)
Local 1 (1) © 9 (5)
Configuration at completion –no. (%)
Conventional tube graft 104 (60) 2 (1) †
Conventional bifurcated graft 65 (37) 2 (1) ‡
Endovascular tube graft - 1 (1)
Endovascular monoiliac graft - 6 (4)
Endovascular bifurcated graft 4 (2) © 160 (94)
Procedure aborted 1 (1) © -
Distal anastomosis –no. (%)
Aorto-aortic graft 104 (60) 3 (2)
Other: 69 (40) 165 (96)
Aorto-biiliac 58 159
Aorto-iliac/femoral 8 6
Aorto-bifemoral 3 -
Procedure aborted/converted 1 (0.6) © 3 (2)
Internal Iliac Artery Status –no. (%)
Postoperative relative to preoperative patency ¥
Unchanged 167 (96) 142 (83)
One of two patent lost or sacrificed 6 (3) 25 (15)
One of one patent lost or sacrificed 1 (1)
Both lost or sacrificed 1 (1) 3 (2)
Type of endograft used –no. (%)
Zenith, Cook Inc. 2 © 57 (34)
Talent, World Medical/Medtronic 3 © 46 (27)
Excluder, W.L. Gore and Assoc. Inc 37 (22)
Other § 30 (18)
© Crossovers from open to endovascular repair.
† One crossover from endovascular to open repair and one immediate conversion due to access problems
of an endovascular bifurcated graft.
‡ One immediate conversion due to access problems of an endovascular monoiliac graft and one due to
failed deployment of an endovascular bifurcated graft.
¥ Two patients (one OR and one EVAR) were not at risk for change as bilateral internal iliac arteries were
occluded preoperatively.
§ Other endografts used : AneuRx, Medtronic (N=12); Quantum LP, Cordis Corp. (N=8); Ancure, Guidant-
EVT (N=5); Lifepath, Baxter Healthcare Corp. (N=4); Endologix, Bard/Impra N=1).
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Surgical and Postoperative Data 
Characteristics of the aneurysm-repair procedures are shown in Table 2. In three
patients who were randomly assigned to undergo endovascular repair, the proce-
dure was converted intraoperatively to an open procedure owing to access prob-
lems in two and failed deployment in one. In one patient, who was randomly
assigned to open repair and who had crossed over to endovascular repair, the pro-
cedure was aborted owing to access problems. The aneurysm was left untreated
(Figure 1).
General anesthesia was used in 98.3 percent of patients in the open-repair
group (in all except three of the five patients who crossed over to endovascular
repair) and in 54.9 percent of patients in the endovascular-repair group (P<0.001).
An aortoaortic (tube) graft was used in 59.8 percent of open repairs and in 1.8 per-
cent of endovascular repairs (P<0.001). At least one internal iliac artery was sacri-
ficed (intentionally or unintentionally) in 4.0 percent of patients in the open-repair
group, as compared with 17.0 percent of patients in the endovascular-repair group
(P<0.001). 
Table 3 shows the main surgical and postoperative data. As compared with
open repair, endovascular repair resulted in a significantly shorter duration of sur-
gery (P<0.001), less blood loss (P< 0.001) and blood replacement (P<0.001), a lower
rate of use of postoperative mechanical ventilation (P<0.001), less of a change in
the hematocrit (P<0.001), a shorter stay in the medium care unit and intensive care
unit (P<0.001), and a shorter hospital stay (P<0.001).
Endpoints and Adverse Events
The operative mortality rate was 4.6 percent in the open-repair group (8 of 174
patients; 95 percent confidence interval, 2.0 to 8.9 percent) and 1.2 percent in the
endovascular-repair group (2 of 171 patients; 95 percent confidence interval, 0.1 to
4.2 percent), resulting in a risk ratio of 3.9 (95 percent confidence interval, 0.9 to
32.9; P=0.10) (Table 4). The combined rate of operative mortality and severe com-
plications was 9.8 percent in the open-repair group (17 of 174 patients; 95 percent
confidence interval, 5.8 to 15.2 percent) and 4.7 percent in the endovascular-repair
group (8 of 171 patients; 95 percent confidence interval, 2.0 to 9.0 percent),
resulting in a risk ratio of 2.1 (95 percent confidence interval, 0.9 to 5.4; P=0.10).
The combined rate of operative mortality and moderate or severe complications
was 23.6 percent in the open-repair group (41 of 174 patients; 95 percent confi-
dence interval, 17.5 to 30.6 percent) and 18.1 percent in the endovascular-repair
group (31 of 171 patients; 95 percent confidence interval, 12.7 to 24.7 percent),
resulting in a risk ratio of 1.3 (95 percent confidence interval, 0.9 to 2.0; P=0.23).
Table 4 shows the rates of operative complications according to class and
grade for the two groups. As compared with endovascular repair, open repair
resulted in a higher rate of moderate and severe systemic complications as well as
a higher rate of severe complications. The majority of the difference was due to a
higher rate of pulmonary complications in the open-repair group (10.9 percent vs.
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Table 3
Surgical and Postoperative Data, According to Treatment.*
Open Endovascular p-value
Repair Repair
Characteristic (N=174) (N=171)
Duration of surgery –min (mean) 151 135 <0.001
Median (Interquartile Range) 150 (120-170) 120 (105-150)
Estimated blood loss –ml (mean) 1654 394 <0.001
Median (Interquartile range) 1500 (900-2300) 250 (100-500)
Autologous blood returned –ml (mean±SD) 486±482 - ¥
Median (Interquartile range) 420 (0-726) -
Homologous blood transfused –units (mean) 0.44 0.09 <0.001
Median (Interquartile range) 0 (0-0) 0 (0-0)
Intraoperative blood transfusion –% (95% CI) 72 (64-78) 6 (3-11) <0.001
Homologous blood products used –% (95% CI) † 21 (15-28) 4 (2-9) <0.001
Intravenous Contrast –ml (mean±SD) - © 167±63
Median (Interquartile range) - 150 (120-200)
Total fluoroscopy time –min (mean±SD) - © 25±18
Median (Interquartile range) - 21 (14-28)
Duration of MCU or ICU stay –hours (mean) ‡ 72 16 <0.001
Median (Interquartile range) 23 (21-47) 3 (0-20)
Postoperative mechanical ventilation –% (95% CI) 51 (43-58) 6 (3-10) <0.001
Duration of postop. mech. ventil. –hours (mean) 34 5 <0.001
Median (Interquartile range) 1 (0-6) 0 (0-0)
Duration of hospitalization –days (mean) 13 6 <0.001
Median (Interquartile range) 10 (8-15) 4 (3-6)
Hematocrit change –L/L (mean) †† 0.09 0.07 <0.001
Median (Interquartile range) 0.09 (0.05-0.12) 0.07 (0.04-0.10)
Decrease of 20% or more –% (95% CI) 53 (44-61) 35 (27-43) 0.002
Creatinin change (mean) ‡‡ -0.5 -5.4 0.93
Median (Interquartile range) 7 (–6-17) 7 (–6.3-10)
Increase of 20% or more –% (95% CI) 13 (8-19) 13 (8-20) 1.00
* Plus-minus values are means ± SD; CI denotes confidence interval.
¥ Autologous blood was returned in 3 patients who were converted from endovascular repair to open
repair: 412, 700, and 1000 ml.
© In 5 patients who crossed-over from open to endovascular repair the volume of intravenous contrast used
was: n/a, 120, 129, 200, and 200 ml; and the total fluoroscopy time was: n/a, 13, 37, 39, 40 min.
† Homologous blood products: Packed cells; Fresh frozen plasma; Cryoprecipitate; Platelets.
‡ Medium Care Unit (MCU) or Intensive Care Unit (ICU) stay included recovery room stay.
†† Hematocrit change (preoperative minus postoperative [day1]) in L/L: OR: 140 (80%) pairs available;
EVAR 136 (80%) pairs available.
‡‡ Creatinin change (preoperative minus postoperative [day2]) in mmol/L: OR: 161 (93%) pairs available;
EVAR 134 (78%) pairs available.
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2.9 percent). Local-vascular and implant-related complications tended to be more
frequent after endovascular repair than after open repair, but the difference was
significant only for moderate or severe complications. There were no significant dif-
ferences between the groups in the rate of local-nonvascular complications.
5.4 Discussion
When taken together, the findings of this randomised trial comparing open and
endovascular aneurysm repair suggest that in patients who qualify for either pro-
cedure, endovascular repair is preferable to open repair over the first 30 days after
the procedure.
To clarify these findings, some issues need to be addressed. The size of the
study group was chosen so that we could demonstrate at least a 10 percent
absolute difference in the primary outcome. Owing to time restrictions imposed by
the sponsor, the ultimate size of the patient group was 12 percent lower than anti-
cipated. In addition, although our estimate of a 20 percent rate of the primary end
point after open repair was accurate (23.6 percent had such an end point), the rate
after endovascular repair turned out to be higher than expected (18.1 percent,
rather than 10 percent). When designing the trial, we anticipated that the rate of
moderate complications after open repair would be considerable. To avoid over-
looking a significant difference in the outcome accounted for by differences in the
rate of moderate complications, we incorporated these into the combined primary
end point. Many of the complications included in the Society for Vascular
Surgery/International Society for Cardiovascular Surgery definition of moderate
complications are important for the postoperative care of patients with abdominal
aortic aneurysm and for the assessment of cost-effectiveness. However, after an
analysis of all moderate complications, the outcome adjudication committee con-
cluded that these complications were unlikely to have an appreciable effect on clini-
cal decision making. 
As compared with open repair, endovascular repair resulted in significantly bet-
ter perioperative outcomes, such as a lower rate of systemic complications (mainly
pulmonary), less blood loss, a briefer duration of surgery, a lower rate of use of
postoperative mechanical ventilation, and shorter hospital stays, all reflecting the
less invasive nature of the endovascular approach. These results are consistent with
those of previously reported series and systematic reviews.
8-15
This advantage, in
combination with a near-significant advantage of endovascular repair over open
repair in terms of operative mortality and combined operative mortality and severe
complications, makes a compelling case for endovascular repair. The risk ratio for
operative mortality was 3.9 for open repair as compared with endovascular repair,
with a 95 percent confidence interval of 0.9 to 32.9. 
We are aware of three other randomised trials comparing open repair with
endovascular repair: the Endovascular Aneurysm Repair (EVAR-1) trial in the United
Kingdom, the Anévrisme de l'aorte abdominale: Chirurgie versus Endoprothèse
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Table 4
Operative Complications, According to Treatment Group.*
Open EVAR Risk Ratio P-
N=174 N=171 (95% CI) value
no. of patients (%)
Endpoints†
Operative mortality  8 (4.6) 2 (1.2) 3.9 (0.9-32.9) 0.10
Operative mortality and severe morbidity 17 (9.8) 8 (4.7) 2.1 (0.9-5.4) 0.10
Operative mortality and moderate/severe morbidity 41 (23.6) 31 (18.1) 1.3 (0.9-2.0) 0.23
Complications ††
Systemic
moderate and severe 46 (26.4) 20 (11.7) 2.3 (1.4-3.8) <0.001
severe 19 (10.9) 6 (3.5) 3.1 (1.3-9.1) 0.01
Cardiac 10 (5.8) 9 (5.3)
severe 2 3
Pulmonary 19 (10.9) 5 (2.9) 3.7 (1.5-11.9) 0.005
severe 8 2 3.9 (0.9-32.9) 0.10
Renal 2 (1.2) 2 (1.2)
severe 1 0
Cerebrovasc/spinal cord 2 (1.2) 1 (0.6)
severe 2 1
Ischemic bowel 2 (1.2) 1 (0.6)
severe 2 0
Other 11 (6.3) 2 (1.2) 5.4 (1.4-53.5) 0.02
severe 4 0
Local/Vascular
moderate and severe 15 (8.6) 28 (16.4) 0.5 (0.3-0.9) 0.03
severe 9 (5.2) 7 (4.1) 1.3 (0.5-4.0) 0.80
(Anastomotic) hemorrhage 6 (3.5) 3 (1.8)
severe 6 1
Graft complications 0 (0.0) 6 (3.5)
severe 0 1
Graft infection 2 (1.2) 1 (0.6)
severe 0 0
Endoleak intervention 0 (0.0) 2 (1.2)
severe 0 1
Thromboembolic 2 (1.2) 2 (1.2)
severe 1 0
Main renal artery obstruction 0 (0.0) 3 (1.8)
severe 0 1
Arterial or graft obstruction 5 (2.9) 11 (6.4) 0.5 (0.1-1.2) 0.13
severe 2 3
Local/Nonvascular
Wound complications 6 (3.5) 6 (3.5)
severe 2 1
Iatrogenic bowel perforation (severe) 1 (0.6) 0 (0)
* The standards of the Society for Vascular Surgery/International Society for Cardiovascular Surgery were
used.
† For end points, only the most severe event in each patient was counted.
†† For complications, all events that occurred in each patient were counted.
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(ACE) trial in France, and the Open versus Endovascular Repair (OVER) trial in the
United States. Whereas the last two trials are ongoing, the results of the EVAR-1
trial have been published recently and are similar to our results.
24
Our trial and the
EVAR-1 trial are almost equivalent in terms of patient selection (patients with low
surgical risk) and outcome criteria. Combining the results of the two trials yields the
most accurate approximation of the risk ratio for in-hospital death to date: an oper-
ative mortality of 5.8 percent in the open-repair group (40 of 690 patients; 95 per-
cent confidence interval, 4.2 to 7.8) and of 1.9 percent in the endovascular-repair
group (13 of 702 patients; 95 percent confidence interval, 1.0 to 3.2), resulting in
a risk ratio of 3.1 (95 percent confidence interval, 1.7 to 6.2). 
Although our results for endovascular repair compare well with those in the lite-
rature, there is some variation in reported operative mortality rates after open
repair among our randomised trial and the randomised EVAR-1 trial, historical and
recent population-based studies,
9,10,25
and the FDA phase 2, pivotal, concurrent,
controlled endograft trials.
12-15
Before the endovascular era, population-based
series reported operative mortality rates of approximately 8 percent,25 whereas
recent nationwide or statewide series have reported rates of approximately 4 per-
cent.
9,10
This difference can be explained by the acceptance of a larger proportion
of high-risk patients for open repair as the only available option in the older series.
Operative mortality rates in the open-repair (control) groups in the FDA phase 2
trials ranged from 0 to 2.7 percent, but these were highly selected patients. The
recent population-based series with an operative mortality of approximately 4 per-
cent can be considered a valid representation of the true operative mortality rate
for open repair and compares well with the results of our randomised trial of
patients with low surgical risk. It is hard to predict whether the overall population-
based mortality associated with aneurysm repair would decrease with the wide-
spread use of endovascular repair, since its use in a broader range of patients
might diminish some of the benefits that we and others have identified.
9,26
Patients in our trial had to be eligible for either operation in order to undergo
randomisation. Consequently, our findings may not be generalizable to patients
who are not suitable candidates for open repair. These patients frequently have
multiple manifestations of advanced atherosclerotic disease and are at increased
operative risk. Neither can our data be generalized to patients who are not suitable
for endovascular repair, since these patients are likely to have more challenging
anatomy.
7
Moreover, a patient's eligibility for endovascular repair is dependent on
the state of device technology. The introduction of fenestrated and branched endo-
grafts is expected to increase the proportion of patients with abdominal aortic
aneurysm who can be treated by endovascular repair in the near future.
27
Age is a well-known predictor of mortality after repair of abdominal aortic
aneurysm. Open and endovascular repair may yield similar results in relatively
young patients at low surgical risk, whereas the latter approach may be particular-
ly advantageous in older and high-risk patients.
28
The size of our trial is not suffi-
cient to permit a meaningful subgroup analysis of the effect of age or coexisting
conditions on the difference in outcome between open repair and endovascular
repair. Other larger and longer-term trials are needed to explore this issue further.
The sponsor of the current trial has funded an extension of the follow-up period for
a total of seven years after surgery; thus, our data address only the perioperative
issues. 
The ultimate decision regarding which type of repair should be used in a given
patient with an abdominal aortic aneurysm is based on a number of factors, includ-
ing the quality of life expected postoperatively, cost-effectiveness, risk of sexual dys-
function, risk of aneurysm rupture, and reintervention rate.
29
These factors must be
considered before a final decision is reached. Our results indicate that in patients
who are candidates for both techniques, endovascular repair is preferable to open
repair, given its lower rates of operative mortality and complications and the signif-
icant reduction in the rates of systemic complications.
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Abstract
Purpose
To compare the quality of life (QoL) in the first postoperative year after elective
endovascular abdominal aortic aneurysm repair (EVAR) and open repair (OR) in a
randomised study. 
Methods
In the Dutch Randomised Endovascular Aneurysm Management (DREAM) trial,
patients are randomly allocated to EVAR or OR. QoL questionnaires (SF-36 and EQ-
5D) were sent to all patients preoperatively (PREOP) and at five time points in the
first postoperative year (3W, 6W, 3M, 6M and 12M). Between November 1999 and
August 2002, 153 patients (141 male; 12 female) were randomised (78 EVAR and
75 OR; one crossover from OR to EVAR). The EQ-5D scores and the eight domains
of the SF-36 for the two groups were compared using the Mann-Whitney test.
Changes over time were analysed using the Wilcoxon sign test. 
Results
There were no statistically significant differences in baseline characteristics (age,
gender and SVS risk factors). The preoperative QoL scores of the study group were
similar to the QoL scores of the general population of the same age. After 3W the
OR group showed a significant decrease on the EQ-5D (p=0.022) and in six of the
eight SF-36 domains. The EVAR group also showed a significant decrease on the
EQ-5D (p=0.004) and in 5 of the 8 domains of the SF-36. At 6W the EQ-5D had
recovered to baseline in the OR group and the decreased domains of the SF-36 had
partially recovered. In the EVAR group the EQ-5D and three of the five decreased
SF-36 domains, had returned to baseline. From 6M on, the OR group reported a
significantly higher score on the EQ-5D than the EVAR group (p=0.045 (6M) and
p=0.001 (12M)). 
Conclusion
In the early postoperative period there is a small, yet significant QoL advantage for
EVAR compared to OR. At 6 months and beyond, patients reported better QoL
after OR than after EVAR.
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6.1 Introduction
Endovascular abdominal aortic aneurysm repair (EVAR) is less invasive than open
repair (OR). However, EVAR may be complicated by endoleaks and endograft fail-
ure leading to a reintervention rate of about 10% per annum.
1-4
Furthermore, the
long-term outcome of EVAR is still not known. The relatively high reintervention rate
in combination with the uncertainty about the durability of EVAR might result in a
reduced quality of life (QoL). Several studies have been published on this subject,
however, until now there have been no randomised studies comparing the impact
of EVAR and OR on the QoL.
5-8
The aim of our study was to compare QoL in the
first postoperative year after elective EVAR and OR in a randomised study. 
6.2 Patients and Methods
In the Dutch Randomised Endovascular Aneurysm Management (DREAM) trial,
patients suitable for both treatments are randomly allocated to EVAR or OR. The
study design has been described in detail elsewhere.
9
The Institutional Review
Board of all participating hospitals approved the study and informed consent was
obtained from each patient. The study was funded by the Dutch Health Insurance
Council (OG68). 
Between November 1999 and August 2002, 153 patients (141 male; 12
female, mean age 70 years (range 53-85 yrs, SD 6.9) were treated (78 EVAR and
75 OR; one crossover from OR to EVAR). Health related quality of life was meas-
ured using the standardised Medical Outcomes Study Short-form 36-item survey
(SF-36) and the EQ-5D.
10-12
The SF-36 includes a multi-item scale that assesses eight
health domains: 
1. limitations in physical activities because of health problems (PF), 
2. limitations in social activities because of physical or emotional problems (SF), 
3. limitations in usual role activities because of physical health problems (RP), 
4. bodily pain (BP), 
5. general mental health (MH) (physiological distress and well-being), 
6. limitations in usual role activities because of emotional problems (RE), 
7. vitality (VT) (energy and fatigue), 
8. general health perceptions (GH). 
For each domain a score can be calculated ranging from 0 to 100, with higher
scores indicating a better QoL (0=death, 100 perfect health). The EQ-5D consists of
five questions, defining health in terms of mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. Again, higher scores indicate a better
QoL.
The QoL questionnaires (SF-36 and EQ-5D) were sent to all patients preopera-
tively and at five time points in the first postoperative year (3 weeks, 6 weeks, 3
months, 6 months and 12 months). If the questionnaire was not filled out complete-
ly, questions were completed with a telephone call. 
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Statistical analysis
Statistical analysis was performed using SPSS version 11.0 (SPSS Inc., Chicago, IL,
USA). Mean (SD) scores at baseline (preoperative values) and postoperatively were
calculated for both groups. Baseline characteristics (age, gender, SVS risk score) of
both trial arms were compared with student's T-test and Chi-square.
13
Baseline
scores were compared with the scores of general Dutch population of the same
Table 1
Baseline characteristics
OR (N) EVAR (N) Missing (N)
Male:Female 69 / 7 72 / 5
Mean Age (yrs) (range) 69,9 (53-85) 70,5 (55-82)
Diabetes 1
none (0) 72 71
adult onset, diet (1) 3 4
adult onset, insuline (2) 1 1
Tabacco use 2
none or >10yrs ago (0) 39 28
not current, <10 yrs ago (1) 13 17
current, < 1 pack/day (2) 15 28
current, > 1 pack/day (3) 8 3
Hyperlipidemia 10
normal levels (0) 37 44
mild elevation, diet (1) 7 8
strict dietary control (2) 1 1
dietary + drug control (3) 24 21
Hypertension 2
none (0) 40 35
single drug therapy (1) 23 27
2 drug therapy (2) 11 11
> 2 drugs or uncontrolled (3) 2 2
Carotid disease 1
no symptoms (0) 67 67
asymptomatic, but disease (1) 4 1
TIA or temporary stroke (2) 3 5
stroke/neurologic deficit (3) 2 3
Cardiac status 1
asymptomatic, normal ECG (0) 39 44
asympt., remote or occult MI (1) 33 25
stable AP, drug compensated CHF (2) 4 7
Renal status 2
no renal disease (0) 70 69
creatinine < 210 µmol/L (1) 5 6
Pulmonary status 2
asympt., PFT >80% of predicted (0) 64 51
asympt., PFT 65-80% of predicted (1) 9 21
PFT 35-65% of predicted (2) 3 3
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A p-value of less than 0.05 was considered significant. Changes over time
were analysed for each trial arm using the Wilcoxon sign test. 
Changes in time in QoL scores were also calculated relative to the preoperative
level. At each time point, the absolute and relative scores on the domains of SF-36
and the EQ-5D for the trial arms were compared using the non-parametric Mann-
Whitney test. 
To assess responsiveness, a standardised response mean (effect-size) was cal-
culated, i.e. the difference in mean scores at baseline and postoperatively divided
by the standard deviation of the baseline score.
14
An effect-size of 0.2 is defined as
small, one of 0.5 as moderate and one of 0.8 or greater as large.
15
6.3 Results
There were no differences in baseline characteristics (age, gender and SVS risk fac-
tors) between EVAR and OR (Table 1). The comparison of the preoperative QoL
scores of the study group with the scores of the age matched Dutch population is
presented in Table 2. The QoL scores of the study group tended to be lower for seve-
ral domains, but large standard deviations preclude valid statistical conclusions.
With respect to the morbidity and mortality there were no losses to follow-up in
the first year. Cumulative survival at 12 months in the OR group was 89% (SD
3.5%) and 95% (SD 2.6%) in the EVAR group (p=0.21, logrank). In addition, the
cumulative event free survival at 12 months was 72% (SD 5.2%) in the OR group
versus 76% (SD 5.0%) in the EVAR group (p=0.49, logrank). 
The preoperative questionnaire response rate was 83% in the OR group and
97% in the EVAR group (p=0.003, Chi-square). The postoperative response rates for
OR and EVAR were 73% versus 97% (p=0.049) at 3 weeks, 75% versus 86%
Table 2
SF-36 scores (mean+SD) of the Dutch population of 61-70 years, the OR and EVAR group. PF, physical func-
tion; SF, social functioning; RP, role-physical; RE, role-emotional; MH, mental health; VT, vitality; BP, bodily
pain; GH, general health
Domain Population (SD)* OR (SD) EVAR (SD)
PF 71,7 (25,6) 70,8 (22,9) 70,1 (22,8)
SF 82,0 (24,6) 73,6 (22,8) 70,0 (25,3)
RP 67,3 (40,9) 57,4 (44,3) 52,9 (45,5)
RE 81,1 (35,0) 64,8 (44,2) 60,7 (44,0)
MH 76,9 (17,9) 68,8 (19,8) 68,0 (20,1)
VT 67,7 (19,6) 60,4 (20,5) 60,0 (23,3)
BP 70,5 (24,6) 73,1 (27,1) 71,8 (28,2)
GH 61,7 (20,2) 60,8 (18,6) 62,9 (18,5)
* Aaronson NK, et al: Validation, and norming of the Dutch language version of the SF-36 Health Survey in
community and chronic disease populations. J Clin Epidemiol 1998; 51(11):1055-1068
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Figure 1
Changes on the domains of SF-36 over time for OR and EVAR. On the x-axis the eight domains of the SF-36,
on the y-axis the scores. PF, physical function; SF, social functioning; RP, role-physical; RE, role-emotional; MH,
mental health; VT, vitality; BP, bodily pain; GH, general health
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(p=0.08) at 6 weeks, 87% versus 93% (p=0.238) at 3 months, 87% versus 95%
(p=0.097) at 6 months and 91% versus 94% (p=0.346) at 12 months. 
The changes on the domains of SF-36 (health profiles) over time for each trial
arm are shown in Figure 1. At the 3 weeks time point the OR group showed a sig-
nificant decrease compared to baseline level on six of the eight SF-36 domains (PF
p<0.001, SF p<0.001, RP p<0.001, RE p=0.006, VT p<0.001, BP p=0.001, Wilcoxon
sign test). The EVAR group showed a significant decrease on five of the domains of
the SF-36 (PF p<0.001, SF p< 0.001, RP p=0.001, VT p=0.006, BP p=0.01, Wilcoxon
sign test). Six weeks after surgery the OR group showed a partial recovery on all
the impaired domains, significantly for the PF, SF and VT (6W versus 3W, p<0.001,
p<0.001 and p=0.004, respectively, Wilcoxon sign test). In the EVAR group three (SF,
RE, VT) of the five decreased domains had returned to baseline, and PF and RP
showed a partial but significant recovery (6W versus 3W, p<0.001 and p=0.048,
respectively, Wilcoxon sign test). Three months after surgery both groups recovered
at least to baseline level on all domains. There was a significant increase in both
groups on MH (3M vs preop. p<0.001 for OR and p=0.005 for EVAR, Wilcoxon sign
test) and in the OR group also on the GH (p=0.004, Wilcoxon sign test). One year
after surgery, the OR group showed a significantly higher QoL than the baseline
level on three of the eight SF-36 domains (SF<0.001, RE p=0.002 and MH p<0.001).
All other domains were still at baseline level. At this time point, the EVAR group
showed a significant increase on RE (p=0.021) and MH (p=0.001). Moreover, a sig-
nificant decrease compared to the baseline level was reported on PF (p=0.033). 
The EQ-5D scores for groups showed a significant decrease 3 weeks after sur-
gery (OR p=0.022, EVAR p=0.004, Wilcoxon sign test). At the 6 week time interval,
both groups showed a completely recovery to baseline on EQ-5D. For the EVAR
group EQ-5D scores remained at baseline level from 3 months on. The OR group
was still at baseline level at 3 months, but the EQ-5D showed a significant increase
compared to the baseline level at the 6 and 12 months time interval (p=0.028 and
p=0.002, respectively, Wilcoxon sign test). 
Comparing the absolute scores at the 3 weeks time interval between the trial
arms, the OR group had significantly lower scores on PF, SF and RP (p=0.026,
p=0.027 and p<0.001, respectively, Mann-Whitney test). The RP score in the OR
was still significantly lower than in the EVAR group 6 weeks postoperatively
(p=0.034, Mann-Whitney test). Comparing the absolute scores at 12 months
between the two trial arms, the OR scored significantly higher than the EVAR group
on PF (p=0.016), SF (p=0,017), RE (p=0.024), BP (p=0.025) and GH (p=0.024). The
EQ-5D scores did not differ significantly between OR and EVAR until 6 months post-
operatively. However, from that time point on the OR group showed significantly
higher scores than the EVAR group (p=0.045 and p=0.001, 6M and 12M, respec-
tively, Mann-Whitney test). 
The effect-sizes for both groups are shown in Table 3. The impact of the inter-
vention was larger for the OR group than for the EVAR group. At 3 weeks, in the
OR group the effect-sizes were classified as severe on three domains (PF, SF, RP),
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moderate on three domains (RE, VT, BP), no effect on MH, and a slight improve-
ment on GH. In the EVAR group, no severe impact was measured, a moderate
effect on four domains (PF, SF, RP, BP), a mild effect on three domains (RE, VT, GH)
and a small improvement on MH. The impact on the EQ-5D was moderate in both
groups at 3 weeks. Six weeks postoperatively, the impact of the intervention has
decreased but is still severe on the RP, moderate on PF, SF and BP in the OR group,
whereas the impact on the EVAR group has decreased to mild. On year after sur-
gery, a positive impact is seen in the OR group on all domains and the EQ-5D. In
the EVAR group this positive impact is also seen, except for PF, GH and EQ-5D. 
6.4 Discussion
Although quality of life is a complex entity that is difficult to define, patient satisfac-
tion weighs heavily in the decision which treatment is best. In contrast to the num-
ber of studies published about the medical differences between EVAR over OR,
there have been only a handful of studies examining QoL. To our knowledge this is
the first randomised study on QoL after EVAR and OR. 
This study has shown that both EVAR and OR has an impact on the QoL, par-
ticularly in the first 3 weeks after the intervention, causing deterioration on almost
all domains and also the EQ-5D. With regard to the physical domains, this decrease
in QoL is significantly more pronounced in the OR group than in the EVAR group.
Because there were no differences in survival rates or event free survival in the first
year, this can be explained by the differences in invasiveness of the OR compared
to EVAR. This was also shown in the study of Aquino et al., although the first post-
operative measurement took place 1 week after the operation.
6
At the fourth week
measurement, all scores in their EVAR group had returned to the preoperative level.
At our second measurement (6 weeks postoperatively) all decreased scores, except
Table 3
Effect sizes compared to baseline level p-values; Wilcoxon sign test. PF, physical function; SF, social function-
ing; RP, role-physical; RE, role-emotional; MH, mental health; VT, vitality; BP, bodily pain; GH, general health.
3 weeks 6 weeks 3 months 6 months 12 months
OR EVAR p-value OR EVAR p-value OR EVAR p-value OR EVAR p-value OR EVAR p-value
PF -1,2 -0,7 0,008 -0,5 -0,3 0,300 0,1 -0,1 0,230 0,1 -0,2 0,039 0,1 -0,2 0,079
SF -1,4 -0,7 0,003 -0,5 -0,2 0,216 0,2 0,2 0,987 0,3 0,2 0,684 0,6 0,2 0,038
RP -1,1 -0,5 0,013 -0,8 -0,4 0,099 -0,2 0,0 0,302 0,1 0,2 0,906 0,3 0,2 0,484
RE -0,5 -0,2 0,448 -0,2 0,1 0,288 0,1 0,2 0,876 0,3 0,4 0,883 0,5 0,3 0,154
MH 0,0 0,1 0,671 0,2 0,2 0,714 0,4 0,3 0,704 0,5 0,3 0,151 0,5 0,4 0,487
VT -0,7 -0,3 0,169 -0,3 -0,2 0,211 0,1 0,0 0,649 0,3 0,1 0,222 0,2 0,0 0,382
BP -0,6 -0,6 0,836 -0,5 -0,1 0,095 0,1 0,1 0,809 0,3 0,1 0,297 0,3 0,1 0,209
GH 0,1 -0,1 0,167 0,1 0,0 0,348 0,3 -0,1 0,010 0,3 -0,1 0,005 0,4 -0,1 0,004
EQ5D -0,5 -0,6 0,857 -0,1 -0,3 0,426 0,2 0,0 0,646 0,3 -0,2 0,005 0,5 -0,1 0,004
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RP and BP in the OR group, showed a partial but not complete recovery. 
Lloyd et al. compared the baseline level with one postoperative measurement
only, 6 months after surgery.
5
They found a significant deterioration in the domains
of physical function in both groups. In our study and also in the study of Aquino, all
patients had at least returned to their baseline level at that time point. An explana-
tion for this different finding could be that Lloyd performed a paired analysis for all
patients without discriminating between EVAR and OR. In addition, their endovas-
cular group consisted of high-risk patients who were not suitable for conventional
repair. On the other hand, they also compared the OR group with the EVAR group
and found no significant differences. The differently chosen time intervals between
these studies make comparison difficult and also emphasises the point that little is
known about the changes over time. 
One weakness of our study could be the difference in the preoperative and the
3-week postoperative response rate between the EVAR and OR group. We do not
have an appropriate explanation for the difference in preoperative response rate.
Except that for the early postoperative period it could be that more patients were
too ill to fill out the questionnaires in the OR group. Even so, this would support our
conclusion that there is an advantage of EVAR in the early postoperative period.
Another weakness of this study is that the analysis is not longitudinal. However,
missing data is inherent to a QoL study. Providing only longitudinal data would
introduce a selection bias also. 
In our study, the mental function showed no decrease postoperatively and even
increased over time reaching significantly higher scores than the baseline in both
groups. Perkins et al. also reported this.
16
A possible explanation for this is the relief
of the anxiety following repair of the aneurysm. 
The intensive surveillance of EVAR did not seem to result in an impaired QoL,
contrary to suggestions made in the literature.
5,6,17
Current results cannot be
explained by differences in intensity of surveillance as follow-up protocols for OR
and EVAR were the same. 
After 3 months, both groups had regained at least their preoperative level on
all domains. It is remarkable the OR group scored significantly better than the
EVAR group at 1 year postoperatively on five of the eight domains and the EQ-5D,
whereas the groups had similar scores preoperatively. This seems to indicate there
is an advantage in QoL of the OR group over the EVAR group, 1 year postopera-
tively. As elective repair of an AAA is treatment of an asymptomatic condition, it is
by definition hard to actually improve the QoL. As the preoperative QoL in our study
group was lower on several domains of the SF-36 than the scores of the general
population, this may indicate that the knowledge of having a potentially life-
threatening disease does have an impact on the QoL. The increase in QoL 1 year
after AAA repair has been described in other QoL studies, mostly in the OR group,
but also in studies on QoL after other major abdominal surgery.
8,16-18
An expla-
nation may be that people experience a relatively better QoL after a period of
severe illness or major surgery. 
In conclusion, in the early postoperative period there is a small yet significant
QoL advantage of EVAR compared to OR. At 6 months and beyond, patients
reported a better QoL after OR than after EVAR.
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7Sexual dysfunction after conventialand endovascular AAA repair
Resul t s of a randomised trial
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Abstract
Purpose
To assess sexual function in the first postoperative year after elective endovascular
aneurysm repair (EVAR) and open repair (OR) of abdominal aortic aneurysm (AAA). 
Methods
In the Dutch Randomised Endovascular Aneurysm Management (DREAM) trial,
153 patients (141 men; mean age 71 years, range 53-85) were randomly allocated
to EVAR (n=77) or OR (n=76). Sexual functioning was evaluated preoperatively and
at 5 times in the first postoperative year (3, 6, 13, 26, and 52 weeks) using a ques-
tionnaire derived from the Medical Outcomes Study. The proportions of patients
reporting sexual dysfunction for any of 5 aspects (interest, pleasure, engagement,
orgasm, and erection) and any increase in the magnitude of dysfunction were com-
pared between EVAR and OR.
Results
Preoperatively, the proportion of patients reporting sexual dysfunction in at least 1
aspect was 66% for the OR group and 74% in the EVAR group (p=NS). Surgery had
a clear impact on sexual dysfunction. The proportion of patients reporting sexual
dysfunction on at least 1 aspect increased to 79% in the OR group and 82% in the
EVAR group. The magnitude of sexual dysfunction increased in both groups on all
5 aspects at 3 weeks postoperatively, but this was more pronounced in the OR
group (interest: OR p=0.038 vs. EVAR p=0.071; pleasure: OR p=0.009 vs. EVAR
p=0.065; engagement: OR p=0.006 vs. EVAR p=0.054; orgasm OR p=0.023 vs.
EVAR p=0.112, and erection: OR p=0.046 vs. EVAR p=0.030). At 6 weeks, the OR
group still reported a significant increase in 3 aspects (pleasure p=0.031, engage-
ment p=0.010, and orgasm p=0.003), whereas the EVAR group no longer showed
a significant difference. From 3 months on, both groups had returned to baseline.
Conclusions
EVAR and open elective AAA repair both have an impact on sexual function in the
early postoperative period. After EVAR, recovery to preoperative levels is faster
than after open repair, but at 3 months, sexual dysfunction levels are similar in both
groups.
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7.1 Introduction
Open abdominal aortic aneurysm (AAA) repair has been associated with impair-
ment of sexual functioning. Sexual dysfunction after open repair (OR) of AAA is
often attributed to autonomic nerve injury and changes in pelvic blood supply. As
endovascular aneurysm repair (EVAR) does not require dissection in the area of the
iliac bifurcation, it is expected not to affect sexual functioning. However, little is
known about this subject. There is clinical evidence that sexual problems have a
mixed etiology, with physical, medical, social, and psychological components. So, it
is not unlikely that other factors may be responsible for the sexual impairment after
OR also.
1,2
Only a few studies have focused on sexual dysfunction after AAA repair,
most in conjunction with conventional surgery.
3-5
The aim of our study was to assess
sexual functioning in the first postoperative year after elective EVAR and OR in a
randomised study.
7.2 Methods
Study design and patients
In the Dutch Randomised Endovascular Aneurysm Management (DREAM) trial,
153 patients (141 men; mean age 71 years, range 53-85) suitable for both treat-
ments were randomly allocated to EVAR (n=77) or OR (n=76) between November
1999 and August 2002. There was 1 crossover from OR to EVAR, but the analysis
was based on intention to treat. The study design has been described in detail else-
where.
6
The Institutional Review Boards of all participating hospitals approved the
study, and informed consent was obtained from each patient. 
Sexual functioning was assessed on a scale adapted from the Medical
Outcomes Study (MOS),
7
which consists of 5 questions concerning sexual function-
ing (table 1). The questionnaire was sent to all patients preoperatively and at 5 time
points in the first postoperative year (3, 6, 13, 26, and 52 weeks). If the question-
naire was not filled out completely, questions were completed with a telephone call.
Table 1
Medical outcomes study questionnaire on sexual functioning
Do you agree or disagree with the following statements?
Completely Partly Partly Completely
agree agree disagree disagree
a. I'm not interested in sex O O O O
b. I have difficulties in relaxing and enjoying sex O O O O
c. I have difficulties in becoming sexually aroused O O O O
d. I have difficulties in having an orgasm O O O O
e. I have difficulties in getting and/or O O O O
keeping an erection (for men only)
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Table 2
Baseline characteristics according to the SVS/AAVS risk factor.
OR (N) EVAR (N)
Male:Female 69 / 7 72 / 5
Median Age (yrs) (range) 70 (53-85) 70 (55-82)
Diabetes (%)
not available 0 1 (1%)
none (0) 72 (95%) 71 (92%)
adult onset, diet (1) 3 (4%) 4 (5%)
adult onset, insuline (2) 1 (1%) 1 (1%)
Tabacco use (%)
not available 1 (1%) 1 (1%)
none or >10yrs ago (0) 39 (51%) 28 (36%)
not current, <10 yrs ago (1) 13 (17%) 17 (22%)
current, < 1 pack/day (2) 15 (20%) 28 (36%)
current, > 1 pack/day (3) 8 (11%) 3 (4%)
Hyperlipidemia (%)
not available 7 (9%) 3 (4%)
normal levels (0) 37 (49%) 44 (57%)
mild elevation, diet (1) 7 (9%) 8 (10%)
strict dietary control (2) 1 (1%) 1 (1%)
dietary + drug control (3) 24 (32%) 21 (27%)
Hypertension (%)
not available 0 2 (3%)
none (0) 40 (54%) 35 (45%)
single drug therapy (1) 23 (30%) 27 (35%)
2 drug therapy (2) 11 (14%) 11 (14%)
> 2 drugs or uncontrolled (3) 2 (3%) 2 (3%)
Carotid disease (%)
not available 0 1 (1%)
no symptoms (0) 67 (88% 67 (87%)
asymptomatic, but disease (1) 4 (53%) 1 (1%)
TIA or temporary stroke (2) 3 (39%) 5 (6%)
stroke/neurologic deficit (3) 2 (3%) 3 (4%)
Cardiac status (%)
not available 0 1 (1%)
asymptomatic, normal ECG (0) 39 (51%) 44 (57%)
asympt., remote or occult MI (1) 33 (43%) 25 (32%)
stable AP, drug compensated CHF (2) 4 (5%) 7 (9%)
Renal status (%)
not available 1 (1%) 2 (3%)
no renal disease (0) 70 (92%) 69 (90%)
creatinine < 210 µmol/L (1) 5 (7%) 6 (8%)
Pulmonary status (%)
not available 0 2 (3%)
asympt., PFT >80% of predicted (0) 64 (84%) 51 (66%)
asympt., PFT 65-80% of predicted (1) 9 (12%) 21 (27%)
PFT 35-65% of predicted (2) 3 (4%) 3 (39%)
Medication affection sex. function (%) 49 (64%) 39 (51%)
Digoxin 5 (66%) 3 (4%)
Diurectics 12 (16%) 10 (13%)
Calcium-channel blockers 16 (21%) 14 (18%)
Beta-blockers 33 (43%) 26 (34%)
CHF: congestive heart failure, AP: angina pectoris, MI: myocardial infarction, PFT: pulmonary function test.
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For analysis purposes, a patient was considered to report sexual dysfunction for
each of the items if any of the following answers were given: completely agree, part-
ly agree, and partly disagree.
Statistical analysis
Baseline characteristics (age, gender, SVS/ AAVS [Society for Vascular
Surgery/American Association for Vascular Surgery] risk score,
8
and medication) of
patients in both trial arms were compared with the Student t and chi-square tests.
The proportion of patients reporting sexual dysfunction on at least 1 of the 5
aspects and the proportion for each individual aspect of sexual functioning were
calculated and compared between the EVAR and OR groups using the Fisher's
exact test. Changes in the magnitude of sexual dysfunction over time versus the pre-
operative value were analysed with the Wilcoxon signed rank test. Analyses were
performed using SPSS version 11.0 (SPSS Inc., Chicago, IL, USA). P<0.05 was consid-
ered significant. 
7.3 Results
There were no differences in baseline characteristics between the EVAR and OR
groups (table 2). Both pre and postoperatively, there were no significant differences
between the trial arms in the number of patients using any b-blockers, calcium-
channel blockers, digoxin, or diuretics. Preoperatively, 64% of the patients in the OR
group used one or more of these medications compared to 51% in the EVAR group.
In the OR group, 47 patients received an aorto-aortic tube graft and 30 a bifur-
cated graft; in the EVAR group, all endografts were bifurcated except 1 tube graft.
Internal iliac artery patency after surgery was unchanged in 72/77 (94%) patients
assigned to the OR group and 61/76 (80%) patients assigned to the EVAR group
(p=0.017). One or bilateral patent internal iliac arteries were lost in 5 OR and in 14
EVAR patients; in addition, a single internal iliac artery (with preexistent contralat-
eral occlusion) was sacrificed in 1 EVAR patient. Postoperatively, impaired sexual
functioning was reported spontaneously at office visits by 2 patients in the OR
group and by 1 in the EVAR patients.
The preoperative questionnaire response rate was 69% in the OR group and
87% in the EVAR group (p=0.007). The postoperative response rates for OR and
EVAR were 61% versus 66% (p=0.542) at 3 weeks, 61% versus 66% (p=0.542) at 6
weeks, 71% versus 70% (p=0.818) at 13 weeks, 69% versus 68% (p=0.956) at 26
weeks, and 69% versus 67% (p=0.819) at 52 weeks.
The preoperatively reported sexual dysfunction rate (table 3) was high in both
groups; for the individual items, the proportions varied between 48% and 56% in
the OR group and 53% and 60% in the EVAR group. Preoperatively, the percent-
age of patients reporting sexual dysfunction on any of the 5 aspects was 66% in
OR group and 74% in the EVAR group (p=NS). There was no statistically significant
difference in the proportion of patients reporting sexual dysfunction between the 2
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groups for any of the 5 aspects at any time point or for sexual dysfunction in at least
1 aspect.
Nevertheless, surgery did have an impact on sexual functioning in both groups
(figure 1). Three weeks after surgery, the reported rate of sexual dysfunction on any
of the 5 aspects increased to 79% in the OR group and 82% in the EVAR group.
Looking at the reported changes in magnitude of sexual dysfunction at 3 weeks
compared to preoperative values (table 4), the OR group reported a significant
increase on all 5 aspects (interest p=0.038, pleasure p=0.009, engagement
p=0.006, orgasm p=0.023, and erection p=0.046). In the EVAR group, there was
an increased magnitude of sexual dysfunction on all aspects also, but only 1 (erec-
tion p=0.030) reached statistical significance (other aspects not significantly
increased: interest p=0.071, pleasure p=0.065, engagement p=0.054, and orgasm
p=0.112). Six weeks postoperatively, the OR group still reported a significant
increase in the magnitude of sexual dysfunction on 3 aspects (pleasure p=0.031,
engagement p=0.010, and orgasm p=0.003; other aspects not significantly
increased: interest p=0.168 and erection p=0.111). The EVAR group showed no sig-
nificant difference at 6 weeks (interest p=0.674, pleasure p=0.855, engagement
p=0.773, orgasm p=0.768, and erection p=0.519). From 3 months on, both groups
had returned to their preoperative level of sexual functioning.
7.4 Discussion
Few reports addressing the impact of OR and EVAR on sexual functioning have
been published. In the available literature, most studies are retrospective in nature
and focus primarily on impotence and erectile dysfunction after conventional open
AAA repair.
4,5,9
To our knowledge, no randomised study has compared sexual func-
tion after OR and EVAR until now.
Although surgery did not result in a significant difference in the proportion of
patients reporting sexual dysfunction between the 2 groups, the impact of surgery
Table 3
Proportion of patients reporting sexual dysfunction
Sexual 
Dysfunction Pre, % 3 Weeks, % 6 Weeks, % 13 Weeks, % 26 Weeks, % 52 Weeks, %
(aspect) OR EV OR EV OR EV OR EV OR EV OR EV
Interest 48 53 67 77* 70 60 51 55 52 58 45 63
Pleasure 56 55 72 84* 74 65 62 59 58 71 51 70
Engagement 55 60 76 77 77* 58 61 53 66 63 53 64
Orgasm 53 57 72 78 77* 55 60 52 65 59 61 54
Erection 54 57 73 74* 72 58 58 56 60 57 60 54
Any aspect 66 74 79 82 77 68 69 70 76 71 66 69
* Significantly different from Pre at p<0.05.
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on sexual function in the OR group was greater than in the EVAR group. This effect
could be demonstrated despite a higher number of internal iliac arteries being lost
or sacrificed in the EVAR group, which underscores the multifactorial pathogenesis
of sexual dysfunction after surgery.
The preoperative rate of sexual dysfunction on any aspect was  70% in our
study, which may appear high compared to other reports, but there are several pos-
sible explanations for this difference.
3,4
First, we had a better rate of response to our
questionnaire than some other investigators have reported.
3,4,10
The prospective
Figure 1
Proportion of sexual dysfunction for 5 aspects over time in the open and the EVAR groups.
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study design and the willingness of participants to enroll in a randomised trial were
factors in favor of compliance. In a retrospective setting, patients who already have
sexual dysfunction are probably less likely to respond to a questionnaire assessing
sexual functioning. This bias leads to an underestimation of the percentage of
patients having sexual dysfunction.
Another explanation for the high sexual dysfunction rate in our study could be
that the questionnaires were sent after randomisation. The knowledge of having a
potentially life-threatening disease and awaiting an operation may have had an
impact on quality of life and sexual functioning. Furthermore, the incidence of sex-
ual dysfunction increases with age and the presence of comorbidities.
11-13
Vascular
disease, smoking, ischemic heart disease, hypertension, and diabetes are known to
have an impact on sexual function.
10,14,15
Xenos et al. and Lee et al. both performed retrospective studies by sending
questionnaires to all AAA patients who underwent OR and asked them to recall
their sexual function preoperatively and 3 months postoperatively.
3,4
As shown in
other studies and also in ours, the impact of the operation on the quality of life has
faded 3 months after the procedure. As such, this seems an acceptable time frame
to assess sexual functioning. Furthermore, it does not seem likely that sexual
function will change or improve after 3 months, as also shown in our data, so the
reported postoperative sexual dysfunction rate at 3 months appears reliable.
However, as Lee et al. also stated, the incidence of preoperative sexual dysfunction
may be clouded by recall bias in retrospective studies.
4
Many responders probably
remember their sexual function to be better than it really was prior to the opera-
tion. Accordingly, the true prevalence of sexual dysfunction likely will be under-
estimated in these studies. Mulligan and Katz examined libido and erectile function
in elderly men and found that only 15% had sexual intercourse, mostly due to
erectile failure.
16
Also, other studies reported sexual dysfunction rates in the same
range as we found in our study.
17,18
Table 4
Proportion of patients reporting an increase in sexual dysfunction compared to the preoperative situation
Sexual 
Dysfunction 3 Weeks, % 6 Weeks, % 13 Weeks, % 26 Weeks, % 52 Weeks, %
(aspect) OR EV OR EV OR EV OR EV OR EV
Interest 45* 44 35 20 19 26 12 24 17 35
Pleasure 41† 42 33* 29 25 22 18 26 23 24
Engagement 47† 38 40* 17 24 22 24 26 24 38
Orgasm 37* 33 35‡ 16 24 13 21 14 26 27
Erection 31* 53* 22 18 17 19 20 20 22 26
* Significantly different from Pre at p<0.05.
† Significantly different from Pre at p<0.01.
‡ Significantly different from Pre at p<0.005.
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Xenos et al. compared erectile function after OR and EVAR in a retrospective
study design.
3
They found significantly decreased sexual functioning after OR and
no deterioration after EVAR. In our study, no differences where found between OR
and EVAR. A likely explanation for this may be that Xenos' study was not ran-
domised. Despite the fact that baseline characteristics did not differ significantly
between their groups, this retrospective study may have been flawed by bias.
A potential shortcoming of our study is that we did not record information
about the opportunities for sexual activity, i.e., of having a spouse or a partner,
which might have had an effect on the results. Another issue may be the medica-
tion taken by patients with AAA. Apart from the vascular disorder and other risk
factors, some types of medication are known to possibly impair sexual function.
19
However the relationship to a specific type of medication can be difficult to deter-
mine because existing comorbidities affect sexual function also.
Sexual functioning would appear to be an integral part of quality of life (QoL),
which the DREAM trial also assessed.
20
The preoperative QoL scores of the study
group were lower on several domains of the Short Form-36 questionnaire but did
not significantly differ from the scores of the age-matched general Dutch popula-
tion. At the 3-week interval, both trial arms reported a significantly decreased QoL,
but the OR group had significantly lower scores than the EVAR group. At 6 weeks,
both groups showed a (partial) recovery of the QoL. Three months after surgery,
both trial arms had regained their preoperative level. However, as the reported sex-
ual dysfunction in this study is high, this might indicate that sexual activity in this
population does not play an important role.
Another limitation in evaluating sexual dysfunction is that there are no vali-
dated questionnaires available on the issue. The Medical Outcomes Study evalua-
tion we have used was selected as the most appropriate from several nonvalidated
questionnaires.
7
Better tools need to be developed to study sexual function after sur-
gery.
Very few patients reported sexual dysfunction spontaneously at office visits. The
high rate of preoperative sexual dysfunction makes it impossible for this study to
analyse sexual dysfunction in patients who reported normal sexual function pre-
operatively. A much larger study would be needed to have enough power to detect
differences between treatment groups. Taking into account that the preoperative
rate of sexual dysfunction is >65% in the target population and that randomised
studies like these are increasingly hard to conduct, it is unlikely this type of evidence
will ever be available. Nevertheless, reanalysis of the DREAM data will be per-
formed after all the questionnaires are available up to the 24-month follow-up.
In conclusion, sexual dysfunction rates are high in this population, even at the
outset. Endovascular and open elective AAA repair both have an impact on sexual
functioning in the early postoperative period. After EVAR, recovery to preoperative
levels is faster than after open repair, but at 3 months, sexual dysfunction levels are
similar in both groups.
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Cost-effectiveness of endovascular
versus conventional abdominal
aortic aneurysm repair at one year
Resul t s of a randomised trial
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Abstract
Background
With clinical outcome presumed at least similar, and reduced hospital and inten-
sive care unit stay, endovascular repair (EVAR) of aneurysms of the abdominal
aorta (AAA) has been proclaimed beneficial compared to open repair (OR). This
hypothesis was addressed in a randomised trial comparing the costs and balance
between cost and effects of EVAR and OR in the first postoperative year. 
Methods
In a multi-center randomised trial comparing EVAR and OR we randomly assigned
173 to EVAR and 178 patients to OR. Costs, cost-effectiveness and complications
were determined one year after surgery. Uncertainty surrounding the incremental
cost-effectiveness ratios (iCER) in terms of cost per quality adjusted life year (QALY)
gained and per year free of complications gained was addressed by bootstrapping.
Results
By one year ten patients in the EVAR group and twelve in the OR group (chi-square
p=0.7). In the EVAR group 33 patients had had one or more severe complications
and in the OR group 37 patients (chi-square p=0.6). EVAR was associated with an
additional €4.300 (95% CI: 2770 to 5830) direct cost per patient (€18.179 versus
€13.886) and a 0.01 (-0.038 to 0.058) decrease in terms of QALYs (0.72 versus
0.73). For event free survival the majority of the bootstrap estimates indicated that
EVAR tended to result in slightly longer event free survival. Thus, only marginal
short-term health gain may be expected at prohibitive costs.
Conclusion
Presently, in patients suitable for both treatments, EVAR cannot be considered an
efficient alternative for OR and should not be applied routinely.
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8.1 Introduction
Endovascular repair (EVAR) of abdominal aortic aneurysms (AAA) is a less invasive
alternative for conventional open AAA repair (OR).
1
Two randomized trials have
demonstrated a significant reduction in operative (30-day) mortality and severe
morbidity.
2,3
Despite this evidence, a prudent approach remains warranted before
differences in treatment outcome can be fully appreciated.
4-6
In addition to health
benefits, economic and health related quality of life (HRQOL) implications of EVAR
as compared to OR should be considered.
Several studies, including the two randomised trials, have documented reduced
hospital stay and intensive care unit stay after EVAR compared to OR.
2,3,7-9
This
reduction, together with improvement of patient recovery time might result in
reduced immediate costs of AAA repair. However, life-long and frequent follow-up
imaging is advised after EVAR.
10
This may offset an initial cost advantage. We have
shown costs associated with the mandatory long-term surveillance to be consider-
able.
11
In addition to cost advantages other reports have suggested that better quali-
ty of life may be expected after EVAR.
12-14
Patients in whom laparotomy is averted
are expected to recover sooner and to experience better quality of life. We have pre-
viously addressed this issue by specifically looking at HRQOL in patients ran-
domised to EVAR or OR.
15
Only in the early postoperative period we found a statis-
tically significant yet minimal QoL advantage of EVAR over OR. In the second half
of the first year, however, patients reported better QoL after open repair than after
EVAR. This would further level out a possible advantage of EVAR over OR.
Only one randomised trial and a few non-randomised studies comparing costs
of EVAR and OR have been published and results are conflicting.
16-21
To resolve this issue we conducted a multi-center randomised trial allowing a
comprehensive head to head comparison of the balance between costs and effects
after elective EVAR and OR: the Dutch Randomised Endovascular Aneurysm
Management (DREAM) trial. 
8.2 Methods
Study design and patients 
A detailed description of the design and methods of the DREAM trial has been pre-
sented elsewhere.
22
In brief, patients diagnosed with an AAA of at least 5 cm in
diameter who were considered suitable for both techniques, and who had given
written informed consent, were randomly assigned to EVAR or OR. Patients who
needed emergency AAA repair were excluded from the study, as were patients with
inflammatory aneurysms, anatomical variations, connective tissue disease, organ
transplantations and a life expectancy of less than two years. The study was per-
formed according to the principles of the Declaration of Helsinki. The Institutional
Review Boards of all participating hospitals had approved the protocol. For the
present analyses patients with one year on costs and effects were included.
Endpoints
Complications were classified and graded according to the reporting standards of
the Ad Hoc Committee for Standardized Reporting Practices in Vascular Surgery of
The Society for Vascular Surgery/International Society for Cardiovascular
Surgery.
23;24
Three severity grades (mild, moderate, and severe) were distinguished.
Only severe events were considered for the present analyses. 
Quality of life
Health related quality of life was assessed with the EuroQol 5 dimensions question-
naire (EQ-5D) using the summary score based on the tariffs by Dolan.
25
At differ-
ent points in time utility scores were obtained by means of EQ-5D. The EQ-5D
results in a single numeric score that represents the societal valuation of the health
status. A value of 1 represents optimal health, whereas 0 represents death.
Questionnaires were sent to patients at baseline and 3, 6 weeks and 3, 6 and 12
months postoperatively. Using linear extrapolation for the periods between meas-
urements, we calculated the quality-adjusted survival time in terms of quality
adjusted life years (QALY) by determining the individual area under the curve of the
summary score. 
Costs
Direct medical costs were assessed in Euros and calculated per patient. Costs per
patient were calculated by multiplying resource use with unit costs. The volume of
the resource use during admission and follow-up was recorded in the case record
forms (CRF) and completed by means of patient diaries. Additional examinations
specifically performed for study purposes such as additional CTAs in the OR group
were not included in the analysis.  Where unavailable from existing sources, unit
costs were determined in two academic and two peripheral hospitals. A weighted
mean of costs per item was calculated, using the ratio of the patients treated in
academic and peripheral setting.  We based our estimation of average costs per
hospital day (ICU, ward) on a study previously performed in the Netherlands.
26
Costs of outpatient visits, visits to family physicians and home care were calculat-
ed from unit costs reported by the Dutch costing manual issued by the National
Health Insurance Board.
27
Costs of medication were estimated using the pharma-
ceutical compass with addition of the pharmacist's charges. Costs of rarely per-
formed interventions were based on National tariffs.
28
Where necessary unit costs
were adjusted to 2003 values according to National Health Service Costs Index
issued by the National Bureau for Statistics Netherlands.  We also assessed costs
due to losses in productivity associated with sick leave, time, travel and other pri-
vate costs incurred by patients (and their families).Time costs were valued using the
friction cost method
29
To assess actual sick leave the Health and Labour question-
naire was sent to patients together with the quality of life questionnaire.
30
The main cost items are presented in table 2.
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Cost-effectiveness
The primary measure of effect chosen for the economic evaluation was quality
adjusted survival time (QALY). The balance between costs and effects of EVAR as
opposed to OR was expressed in terms of incremental costs per QALY gained. The
incremental cost-effectiveness ratio (iCER) was calculated by dividing the difference
in costs incurred over a period of one year by the difference in (quality-adjusted) life
years. The incremental costs per year without severe complications and per life year
gained were estimated as secondary outcome measures.
The time horizon considered for the current analyses was one year. Accordingly,
discounting costs or effects was not necessary, i.e., time preference for any of the
outcomes was considered negligible.
* Plus-minus values are means ±SD. FEV1 denotes forced expiratory volume in one second, and ASA
American Society of Anesthesiologists. The body-mass index is the weight in kilograms divided by the
square of the height in meters. Because of rounding not all percentages total 100.
† The Society for Vascular Surgery / International Society for Cardiovascular Surgery (SVS/ISCVS) risk-factor
score ranges for each of eight domains from 0 (no risk factors) to 3 (severe risk factors).
23
Total scores
can range from 0 to 24, with higher scores indicating more risk factors. 
¥ No information was available for six patients in the open-repair group and four patients in the endovas-
cular-repair group
Table 1
Baseline characteristics
Open Repair Endovascular Repair
Characteristic (N=167) (N=173)
Age –yr 69.5±6.9 70.5±6.5
Male sex –no. (%) 151 (90) 161 (93)
Mild, moderate, or severe SVS/ISCVS risk-factor score –%†
Diabetes Mellitus 9.0 9.8
Tobacco Use 55.1 64.7
Hypertension 53.9 59.0
Hyperlipidemia 53.4 47.0
Carotid Disease 14.4 14.5
Cardiac Disease 45.5 42.2
Renal Disease 7.8 7.5
Pulmonary Disease 18.6 26.6
Sum of SVS/ISCVS risk-factor scores† 4.4±2.4 4.5±2.5
FEV1 –liters/sec 2.6±0.7 2.5±0.7
Body-mass Index 26.5±4.0 26.3±3.4
ASA class –no. (%) 
I healthy status 40 (24) 38 (22)
IImild systemic disease 103 (62) 121 (70)
III sever systemic disease 24 (14) 14 (8)
Maximum AAA diameter –mm 60.0±8.5 60.6±9.0
Statistical analysis
All analyses were based on all randomised patients who underwent aneurysm
repair. We performed an on-treatment analysis. Mortality and complication rates
at one year were compared between the two trial arms using the Chi-Square test.
Costs and health outcomes are presented as the means per patient.
Differences between the groups are presented with 95% confidence intervals (CIs).
Uncertainty with regard to differences in costs were described by means of 95%
CIs based on the bootstrap replicates of the trial.
31
Uncertainty with regard to the balance between costs and effects was also
evaluated by means of bootstrapping. A total of 10.000 bootstrap replicates were
drawn from the original dataset and for each replicate the incremental costs were
plotted against the incremental effects. By depicting the resulting distributions a
two-dimensional, so-called cost-effectiveness plane (CE-plane) is created represent-
ing the uncertainty surrounding the iCER. 
8.3 Results
Patients and treatment
Between November 2000 and December 2003, 351 patients were randomly
assigned to either EVAR or OR. Six patients did not undergo aneurysm repair after
randomisation: four declined treatment (one assigned to EVAR and three to OR),
and two died (one in each group). Five patients were lost to follow-up in the first
94
C
H
A
P
T
E
R
8
Table 2
Main unit costs
Unit costs Source
Preoperative
Work-up (incl examinations and visits) € 493 cost study
Intra-operative
Operation Room (per hour) € 15 cost study
Anaesthesia (excl personnel)
- OR: university hospital € 436 cost study
- OR: general hospital € 316 cost study
- EVAR: university hospital € 206 cost study
- EVAR: general hospital € 75 cost study
Inpatient hospital days
ward: university hospital € 330 Koopmans et al 
26
ward: general hospital € 240 Koopmans et al 
26
medium care unit € 735 Koopmans et al 
26
intensive care unit € 1.140 Koopmans et al 
26
Investigations
Angiography € 662 cost study
CT angiography € 183 cost study
Duplex scanning € 84 cost study
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year. This resulted in a study group of 340 patients, 170 patients randomised to
EVAR and 170 to OR. There were five crossovers: one patient randomly assigned to
EVAR underwent OR and four patients assigned to undergo OR underwent EVAR.
As patients were analyzed as treated, the OR-group consisted of 167 patients and
the EVAR group consisted of 173 patients.
Baseline characteristics of patients and aneurysms are given in table1.
Demographic characteristics, co-morbid conditions, cardiovascular risk profile, ASA
classifications, and characteristics of the aneurysm were similar in the two groups. 
Endpoints
In the first postoperative year in the EVAR group 33 patients experienced one or
more severe complications and 37 in the OR group (p=0.6). Death occurred in 10
patients in the EVAR group and12 in the OR group (chi-square p=0.7). 
Quality of life
The primary outcome in terms of QALYs one year after randomisation marginally
favoured OR compared to EVAR. Patients that underwent EVAR experienced 0.72
0
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Figure 1
Utility score over time in the first postoperative year after EVAR and OR with 95% CI.
Area under the curve equals QALYs.
QALYs (95% CI: 0.29 to 1.14) and patients that underwent OR experienced 0.73
QALYs (0.27 to 1.19), i.e., a non-significant 0.01 (-0.038 to 0.058) QALY loss was
observed after EVAR (figure 1).
Costs
The average direct costs per patient per randomisation group are presented in
table 3. At one year, the total direct costs of EVAR were €4.300 (2770 to 5830)
higher per patient than those of OR (€18.179 versus €13.886). The greater part of
the cost difference was attributable to costs of the endoprosthesis, and also the
costs of the obligatory surveillance of the EVAR group contributed to the difference.
Only 24 patients still had paid employment, making the costs of loss in productivi-
ty minimal (table 3). Focusing on those 24 patients, the costs due to sick leave were
made by 11 patients in the EVAR group (mean €3820, SD 3440) and13 patients in
the OR group (mean €4662, SD 3558). 
Cost-effectiveness
The iCER per year without severe complications was €76.100. The iCER per life year
gained was €171.500. In terms of QALYs, OR appeared to be the dominant
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Table 3
Average direct costs per patient per treatment group in the first postoperative year.
Open repair Endovascular repair
N=167 N=173
Costs SD Cost SD
Direct costs in hospital € 11.880 8.621 € 14.955 4.194 
Operation € 5.500 1.213 € 2.724 2.507 
Use of OR € 546 14 € 306 96 
Personnel OR € 4.269 1.089 € 3.771 1.277 
Conventionel prosthesis € 500 0 € 6 54 
Endovascular prothesis € 7.911 1.785 
Other materials € 184 415 € 731 620 
Admission (ward+ICU) € 6.090 7.864 € 2.127 2.825 
Additional costs (investigations, medications etc) € 291 1.225 € 103 364 
Direct costs during follow-up (1 yr) € 1.711 1.934 € 3.588 3.293 
Standard follow-up € 253 66 € 832 133 
complications € 277 149 € 1.315 2.284 
sick leave € 363 1.576 € 243 1.250 
outpatient health care* € 819 1.116 € 1.198 2.175 
TOTAL# € 13.592 8.761 € 18.542 5.157 
* N=149 for OR and N=156 for EVAR
# Trial based estimate of difference in costs almost €5000. We used the bootstrap replications to obtain
an accurate estimate and pertaining uncertainty.
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Figure 2
CE-planes. The CE-plane consists of 4 quadrants. A dot to the right of the vertical axis means that EVAR is
better, whereas a dot on the left side means the OR is better. Likewise, a dot above the horizontal axis means
that the costs of EVAR are higher, whereas a dot below the horizontal axis implies that OR is more expensive.
The given percentages represent the proportion of bootstrap replication in which the clinical outcome favours
OR. The oblique line in c indicates a societal willingness to pay a threshold of € 25.000 per QALY.
a. event free years gained
b. life-years gained
c. QALYs gained
strategy, i.e., costs were lower and better results were observed, albeit marginally
and non-significant.
Results of the bootstrapping are depicted in CE-planes in figure 2. The panels
2a (event free years gained) and 2b (life-years gained) show that respectively 95%
and 85% of the replicates were in the right upper quadrant. This indicates that with
high certainty EVAR had favourable health outcomes, but against higher costs.
Figure 2c (QALYs gained) shows that most (65%) replicates were in the left upper
quadrant, indicating that we can be 65% certain that OR yields a marginally bet-
ter outcome in terms of QALYs at one year. The oblique line indicates a societal will-
ingness to pay a threshold of €25,000 per QALY. (Society is usually willing to pay
for interventions with an iCER below that threshold). All replicates lie above this
threshold indicating that with 100% certainty OR can be considered the preferred
strategy from a health economic perspective. 
8.4 Discussion
The results of the present economic evaluation indicate that, although there may
be a limited (early) survival benefit of endovascular repair over open repair, costs
are prohibitive. Moreover, in terms of costs per QALY gained there was an indica-
tion of open repair being the dominant strategy, i.e., the costs after open repair
were higher and the QALYs experienced were fewer. Similar to our findings, the
EVAR-1 trial showed a non-significant difference in QALYs, in favour of open
repair.
16
The fact that the aneurysm-related complication-free survival benefit with
endovascular repair persisted for two years, again corroborated by the EVAR-1 trial,
should be seen in the context of identical all cause mortality rates after about one
year after randomisation.
16,32
Comparable results were reported by Forbes et al who performed a cost-effec-
tiveness analysis by retrospectively analysing data of 40 patients (7 endovascular
repair, 31 open repair) electively treated for an AAA, taking into account the in hos-
pital costs and the costs of secondary interventions and surveillance.
33
Contrary,
some early studies using a Markov-model suggested that endovascular repair was
cost-effective compared to open repair. 
20,21
These results are in strong contrast with
our findings that the incremental costs associated with endovascular repair are
considerably higher compared to open repair in the first year after surgery, while
in terms of QALYs we even observed a net loss. A plausible explanation for this dif-
ferent finding is that among others Patel et al. used the initial and apparently opti-
mistic results of endovascular repair for her model, with a combined mortality and
severe morbidity rate of 1.1% for endovascular repair versus 9.1% for open
repair.(20) She did, however, conclude that the cost-effectiveness of endovascular
repair is critically dependent on its potential to reduce morbidity and mortality
rates. The currently available results, including the results of the randomised trials,
have shown that these rates are much closer to each other.
16,32
The two randomised trials (EVAR1-trial and DREAM) provided sound evidence
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of a short-term benefit of endovascular repair over open repair in terms of opera-
tive mortality and complications.
2,3
Also, both trials reported a significant reduction
in length of stay, intensive care use, systemic complications, and use of other
resources. For this reason, endovascular repair was expected to lead to significant
savings in hospital costs. However, using actual costs data this could not be con-
firmed. The savings realised were offset, for the majority, by the costs of the endo-
prosthesis, which is eight to ten times more expensive than the conventional pros-
thesis. Sternberg and Money found that the costs of the endoprosthesis accounted
for 52% of the total endovascular repair costs.
17
Likewise, in the study by Berman
et al 70% of the costs of endovascular repair were attributed to the endoprosthe-
sis, whereas in the open repair group 75% of the costs were accounted for by hos-
pital care outside the operating room.
18
A drawback of these two studies and also
other studies on costs of endovascular repair and open repair is that none of them
were based on a randomised design. This may have resulted in selection bias, espe-
cially as endovascular repair was initially meant for use in patients unfit for open
repair. Nevertheless, the data of the present randomised trial show similar results
with regard to initial intervention related costs. 
Another flaw of most available cost studies is that they focussed on in-hospital
costs only.
19,33
A comprehensive cost analysis should also include the costs of pre-
operative and postoperative radiological studies, the costs of preoperative and sec-
ondary interventions, the costs of the procedure itself, and finally the costs associ-
ated with regular follow-up. Endovascular repair is known to sometimes result in
specific complications, such as endoleak and endograft migration, kinking and rup-
ture, rarely observed after open repair.
34-36
Therefore, lifelong intensive follow-up is
considered mandatory after endovascular repair. Moreover, besides the accumulat-
ing costs of follow-up, a reintervention rate after endovascular repair as high as
10% per annum has been reported.
37
Presently, the intensity of the follow-up
scheme is under discussion. Possibly, the currently available devices with fewer sec-
ondary interventions permit a less intense follow-up scheme using less costly diag-
nostic techniques.
38
In the future, this could overcome part of the cost disadvantage
of endovascular repair, yet only a substantial drop in the price of the devices could
really tilt the balance. 
An apparent limitation of our study is that the analysis was limited to one-year
data, and, as mentioned above, might become outdated as newer generations of
endoprostheses become available. If indeed devices were to be improved and rein-
tervention rates would drop in the following years, this will have an impact on the
costs and possibly effects. Note, however, that even a slightly higher reintervention
rate after endovascular repair will remain offsetting the balance in favour of open
repair. In fact, because we only used a one year time horizon, the present analyses
may be considered conservative with regard to the cost-effectiveness advantage of
open repair over endovascular repair. Laheij et al showed that the reintervention
rate does not decrease up to four years after endovascular repair in a large study
using Eurostar data.
37
Also, the EVAR-1 and EVAR-2 trials recently showed 9% and
26% reinterventions four years after endovascular repair, in patients potentially fit
to undergo open repair, and unfit for open repair, respectively (EVAR-1 en EVAR-2). 
In conclusion, endovascular repair cannot be considered an efficient alternative
for open repair, and should not be applied routinely. Whether endovascular repair
will ever become cost-effective, particularly on the long-term, remains to be seen.
Long-term data from the randomised trials will shed new light on the issue. If qual-
ity of life, complication rates, and survival after endovascular repair were to
improve, and if the costs of the devices would come down the cost-effectiveness
might change in favour of endovascular repair. 
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Abstract
For this meta-analysis on the effects of endovascular repair of abdominal aortic
aneurysm (AAA) compared to conventional open repair, PubMed was searched
from inception up to December 31, 2004: (("Aortic Aneurysm"[MAJR] OR "Aortic
Aneurysm, Abdominal"[MAJR]) OR (Aort*[tiab] AND Aneurysm[tiab])) AND (ran-
dom*). Related citations were scrutinised via PubMed and Web of  Science.
Selected were publications of randomised trials comparing endovascular with
open repair of AAA, that reported quantitative data on either or both mortality and
morbidity in sufficient detail to allow statistical pooling. Data were analysed using
the EASYMA software package, using a random effects model with inverse variance
weighting.
The 30-day-mortality data of 2 randomised trials (EVAR-1 and DREAM) allowed
pooled analysis. The resulting mortality risk difference -0.04 (-0.07 ; -0.02, P<0.001)
and mortality risk ratio 0.44 (0.27 ; 0.70, P<0.001) favoured endovascular repair. 
The obtained mortality risk reduction of 56% (number needed to treat: 24)
implies that endovascular AAA repair is to be preferred over the conventional open
AAA repair. Still the accrued amount of person years of follow-up is rather limited.
With accrual of person years of follow-up the non-randomised FDA-approval
studies recently revealed an important increase in the number of serious adverse
events for endovascular AAA repair. Hence, further evidence on the benefit risk
ratio and the cost-effectiveness from long term follow-up of the EVAR-1 and DREAM
trials and other currently conducted trials should be awaited before deciding on full
scale use of endovascular AAA repair.
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9.1 Introduction
Abdominal aortic aneurysm (AAA) is a balloon-like bulge in the aorta, the main
artery in the body.  The prevalence of AAA depends on the definition, in particular
on its diameter. Estimates therefore range between 1% and 9%.
1,2
Men above 60
years of age, female smokers above 60 years of age, and persons with a history of
peripheral or coronary artery disease have an increased risk for AAA.
3
Three out of
four aneurysms show no symptoms at the time they are detected. When symptoms
are present, they may include: abdominal pain (that may be constant or come and
go); pain in the lower back that may radiate to the buttocks, groin or legs; the feel-
ing of a "heartbeat" or pulse in the abdomen. Mortality of patients with an AAA is
high; in about 85% of all patients a rupture of an AAA is fatal. The annual rupture
risk depends on the diameter of the aneurysm: below 1% for a diameter below 4
cm; up to 5% for 4 cm; up to 15% for 5 cm; up to 20% for  6 and 7 cm; up to 50%
for 8 cm or larger.
4
With about 50%, operative mortality of emergency surgery of
those who reach theatre alive is also very high.
5,6
To prevent rupture of AAA elective repair is preferred. In patients with normal
surgical risks and an AAA below a diameter of 5,5 cm, the estimated risk of the rup-
turing and subsequent death is lower than the estimated risk of elective open sur-
gical repair. Once an aneurysm reaches 5,5 cm in diameter, treatment to prevent
a rupture is generally considered necessary.
7
During elective open surgical repair a
midline laparotomy and aortic crossclamping is required. Operative mortality of
elective surgical repair is estimated at 7%.
8
Durability of the conventional graft has
been proved excellent while its failure rate is about 0.3 percent per year.
9,10
For
open surgical repair about 14 days of hospitalisation is needed.
About a decade ago, an endovascular procedure was introduced.
11
A long flex-
ible delivery tube containing a graft is inserted through a small incision in the
femoral artery. Under radiologic guidance (fluoroscopy) the graft is delivered and
secured inside the aneurysm. The graft is intended to exclude the AAA from the cir-
culation and thereby prevent further growth and possible rupture of the aneurysm. 
Our aim was to pool the published outcomes of randomised trials comparing
the endovascular and open techniques for elective AAA repair into a single com-
bined estimate of effect.
9.2 Methods
Appropriate publications were retrieved from PubMed from inception up to
December 31, 2004, with the following combination of indexed subject terms:
(("Aortic Aneurysm"[MAJR] OR "Aortic Aneurysm, Abdominal"[MAJR]) OR
(Aort*[tiab] AND Aneurysm[tiab])) AND (random*). Selection of publications was
based on screening of titles and abstracts for randomised phase-3 trials comparing
endovascular with open repair of AAA, that reported data on either or both mortal-
ity and morbidity with sufficient detail to allow statistical pooling. For all retrieved
randomised trials and meta-analyses on treatment of AAA the "related articles" in
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PubMed and the linked citations in Web of Science were screened for additional rel-
evant titles. We extracted data on treatment and outcomes, and pooled these sta-
tistically with the EASYMA program
12,13
using a random effects model with inverse
variance weighting.
14
9.3 Results
In total 396 titles were retrieved. Ten of these
15-24
with their linked citations were
scrutinised for inclusion, but only 2 randomised trials qualified for statistical pool-
ing: the Endovascular Aneurysm Repair (EVAR-1) study from the United Kingdom
and the Dutch Randomised Endovascular Aneurysm Management (DREAM)
trial.
23,24
Both EVAR-1 and DREAM trials include a considerable number of ran-
* Pooled estimates for overall mortality at 30 days based on patients as randomised, obtained with
EASYMA using a random effects model with inverse variance weighting.
Table 1
Data extracted from both trials
OR EVAR
no. of patients (%)
Patients randomised
DREAM 178 173
EVAR-1 539 543
Refused surgery
DREAM 3 (1.69) 1 (0.58)
EVAR-1 9 (1.67) 2 (0.37)
Died before surgery
DREAM 1 (0.56) 1 (0.58)
EVAR-1 14 (2.60) 10 (1.84)
Treatment conversion
DREAM 5 (2.81) 4 (2.31)
EVAR-1 17 (3.15) 15 (2.76)
Died after surgery
DREAM 8 (4.49) 2 (1.16)
EVAR-1 32 (5.94) 11 (2.03)
Total dead (with best-case assumption for refusers) RR (95%CI) RD(95%CI)
DREAM 9 (5.06) 3 (1.73) 0.34 (0.09;1.25) -0.03 (-0.07;0.004)
EVAR-1 46 (8.53) 21 (3.87) 0.45 (0.27;0.75) -0.05 (-0.08;-0.02)
Pooled estimate* (95% CI) 0.44 (0.27;0.70) -0.04 (-0.07;-0.02)
Heterogeneity Q=0.156 (df=1) with p=0.69 Q=0.312 (df=1) with p=0.58
Total dead (with worst-case assumption for refusers)
DREAM 12 (6.74) 4 (2.31) 0.34 (0.11;1.04) -0.04 (-0.09;-0.001)
EVAR-1 54 (10.02) 23 (4.24) 0.42 (0.26;0.68) -0.06 (-0.09;-0.03)
Pooled estimate* (95% CI) 0.41 (0.27;0.63) -0.05 (-0.08;-0.03)
Heterogeneity Q=0.115 (df=1) with p=0.73 Q=0.252 (df=1) with p=0.62
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domised patients (Table 1). The reported data for 30-day-mortality for both trials
allow pooled analysis. Pooled re-analysis for other endpoints was limited by discrep-
ancies between the DREAM and EVAR-1 trials in their definition and detail of
reported data. 
Both studies reported a number of randomised patients that either died before
surgery commenced or refused allocated treatment. In both trial reports these
patients were excluded from the analysis. For both trials the mortality risk differ-
ence and the mortality risk ratio at 30 days based on all randomised patients was
re-calculated including those who refused allocated treatment or who died between
allocation and surgery. Hence, the reported pooled analysis includes all patients. 
The results of this meta-analysis show that the overall 30-day-mortality in both
trials is equally low (Table 1). There was no gross heterogeneity, while endovascular
repair resulted in a significant reduction in 30-day-mortality as compared to open
repair (Table 1). Mortality risk difference: -0.04 (-0.07 ; -0.02, P<0.001) and mortal-
ity risk ratio: 0.44 (0.27 ; 0.70, P<0.001). These results hold under the best case
assumption (i.e. survival) for patients who refused treatment. Under worst-case
assumption (i.e. death) these estimates slightly changed (Table 1): mortality risk dif-
ference: -0.05 (-0.08 ; -0.03, P<0.001) and mortality risk ratio: 0.41 (0.27 ; 0.63,
P<0.001).
9.4 Discussion
The results of the EVAR-1 trial
23
and DREAM trial
24
firmly add to the body of evi-
dence on endovascular repair. Up to the reports of both randomised trials the
choice between endovascular and open repair relied on studies without control
groups or with a quasi-experimental design and therefore was not based on suffi-
ciently high levels of evidence.
4,25,26
The results of our meta-analysis show that in
terms of 30-day-mortality endovascular repair leads to a risk reduction of 56%
(NNT=24) that is statistically significant at the conventional level. Based on this
result, endovascular repair for AAA is to be preferred over open repair.
Endovascular graft devices for AAA repair were approved for the first time by
the Food and Drug Administration (FDA) on September 28, 1999.
27,28
The FDA
reported that endografts could successfully be inserted and reduce direct surgical
trauma, and that endograft repair had a lower complication rate and shorter hos-
pital stay than conventional open abdominal repair. However, this FDA approval
has been subject of controversy because it was based on open-label non-ran-
domised cohort studies of effectiveness. 
Open-label non-randomised studies, most notably clinical practice registries,
generally are of less scientific rigor.
e.g. 29-31
They may be affected by confounding-by-
indication; varying compliance with surgical protocols; low adherence to and selec-
tive follow-up; varying standards for endpoints adjudication. It should be noted that
the direction of consequent biases is not by definition towards dilution of effect. But
in general, the benefit-risk ratio and the cost-effectiveness of endovascular repair is
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likely to be diluted after full scale acceptance and use in surgical practice, due to
less strict selection of patients and lower compliance with surgical protocols.
Due to the FDA approval endovascular graft devices have become mainstream
medical technology long before the first randomised trial comparing endovascular
graft repair with open graft repair had been commenced. To date, the Ancure endo-
graft has been used in more than 18.000 persons worldwide
32
, the AneuRx stent
graft in more than 40.000 persons
33
, and the Zenith endograft in more than 12.000
patients
34
. In addition, elective endovascular repair has offered opportunities for
repair of smaller aneurysms at low risk of rupture and for repair in patients with a
high risk for complications with open repair. Currently, the 5-years survival rates for
both endovascular and open repair is about 70%
35-38
,and while for endovascular
repair in-hospital costs are higher
39
it is considered cost-effective on the long run.
40
Still, estimates for long term outcomes and the cost-effectiveness are based on
open-label non-randomised studies, and therefore are surrounded by uncertainty.
Moreover, meta-analyses have shown that both patient characteristics and proce-
dural variables are independent risk factors for complications after endovascular
AAA repair.
41,42
On April 27, 2001, 19 months after the first approval, the FDA issued a Public
Health Notification
43
on problems associated with endovascular grafts for repair of
AAA stating that manufacturers had failed to report about malfunction and integri-
ty problems of the endografts and placing devices. These problems resulted in sev-
eral serious adverse events including endoleaks requiring open repair, as well as
enlarging and rupturing aneurysms. At the same time the FDA acknowledged that
with accrual of person-years of follow-up among patients who underwent endovas-
cular repair in the (non-randomised open label) approval studies, a growing num-
ber of patients experienced serious adverse events. On April 24, 2002
44
and on
May 23, 2003
45
two more endovascular graft systems for the treatment of AAA
were approved by the FDA. On December 17, 2003, 4 years and 3 months after
the first approval, the FDA warned in a Public Health Notification
46
that, based on
long term follow-up of its pre-approval open-label non-randomised cohort studies,
the risk for late mortality associated with AAA endografting is likely to exceed the
mortality associated with open AAA repair.
The latest Public Health and safety notification
46
underpins the need to balance
the short term benefits of endovascular repair with its risks for late complications.
Poor durability of endovascular repair may lead to aneurysm recurrence, graft leak-
age, and eventual conversion to open repair, and will reduce the potential gain in
terms of morbidity, quality of life and costs on the long run. Hence, before drawing
definite conclusions about the effectiveness of endovascular AAA repair, the long
term benefits-risks ratio, as well as the long term cost-effectiveness should be taken
into account.
The pooled results of the EVAR-1 trial
23
and DREAM trial
24
on the 30-day-mor-
tality shown in our meta-analysis are promising. But, to our opinion, the amount of
person years of follow-up accrued to date and the evidence for the cost-effective-
111
M
E
T
A
-A
N
A
L
Y
S
IS
ness is too limited to merit the current full scale acceptance and use of endovascu-
lar repair of AAA in daily surgical practice. Other randomised trials
47-50
and the long
term outcomes of EVAR-1 and DREAM trials await publication. A cumulative meta-
analysis may prevent a delay in applying knowledge and evidence in caring for the
next patients and thereby may guide timely acceptance and use of innovative treat-
ments.
51,52
The Veterans Affairs Open versus Endovascular Repair (OVER) trial
49
,
and the French Aneurysme Chirurgie de l'aorte contre Endoprothèse (ACE) trial
50
make a similar comparison as the EVAR-1 and DREAM trials, and so should be
added to this meta-analysis at a later stage. Such cumulative meta-analysis prefer-
ably uses pooled raw individual patient data, and should focus on whether use of
open repair or endovascular repair should be restricted to specific subgroups
according to risk status.
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Abstract
Background
Two randomised trials have shown better outcomes with elective endovascular
repair of abdominal aortic aneurysms than with conventional open repair in the
first month after the procedure. We investigated whether this advantage is sus-
tained beyond the perioperative period. 
Methods
We conducted a multicenter, randomised trial comparing open repair with
endovascular repair in 351 patients who had received a diagnosis of abdominal
aortic aneurysm of at least 5 cm in diameter and who were considered suitable
candidates for both techniques. Survival after randomisation was calculated with
the use of Kaplan-Meier analysis and compared with the use of the log-rank test on
an intention-to-treat-basis. 
Results 
Two years after randomisation, the cumulative survival rates were 89.6 percent for
open repair and 89.7 percent for endovascular repair (difference, -0.1 percentage
point; 95 percent confidence interval, -6.8 to 6.7 percentage points). The cumula-
tive rates of aneurysm-related death were 5.7 percent for open repair and 2.1 per-
cent for endovascular repair (difference, 3.7 percentage points; 95 percent confi-
dence interval, -0.5 to 7.9 percentage points). This advantage of endovascular
repair over open repair was entirely accounted for by events occurring in the peri-
operative period, with no significant difference in subsequent aneurysm-related
mortality. The rate of survival free of moderate or severe complications was also
similar in the two groups at two years (at 65.9 percent for open repair and 65.6
percent for endovascular repair; difference, 0.3 percentage point; 95 percent con-
fidence interval, -10.0 to 10.6 percentage points). 
Conclusions 
The perioperative survival advantage with endovascular repair as compared with
open repair is not sustained after the first postoperative year. 
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10.1 Introduction
Two randomised trials have demonstrated better outcomes with elective endovas-
cular repair of abdominal aortic aneurysms than with conventional open repair in
the first month after the procedure.
1,2
The reported in-hospital mortality rates in
these two trials were 4.6 percent and 6.0 percent for open repair and 1.6 percent
and 1.2 percent for endovascular repair, respectively. Although the relevance of a
reduction in perioperative risk should not be underestimated from the patient's per-
spective, the improvement in early survival with the use of a less invasive technique
is not surprising.
3
Consequently, both reports stressed the need for longer-term
data before a decision could be reached about which therapy is better in patients
who are suitable candidates for either procedure. 
Findings in uncontrolled long-term studies of endovascular aneurysm repair
have suggested that the early advantage of endovascular over open repair may not
persist over time.
4,5
Endovascular repair appeared to be associated with higher
rates of reintervention and complications as well as a continued risk of aneurysm
rupture. The Dutch Randomised Endovascular Aneurysm Management (DREAM)
trial was conducted to assess the rates of death from any cause and complications
in a multicenter, randomised trial comparing elective open and endovascular
aneurysm repair. 
10.2 Methods 
Study Design and Patients 
The design and methods of the trial have been described in detail elsewhere.
2,6
In
brief, patients referred to surgery clinics at 26 centers in the Netherlands and 4
centers in Belgium who had received a diagnosis of an abdominal aortic aneurysm
of at least 5 cm in diameter and who were considered suitable candidates for both
techniques were randomly assigned to undergo open or endovascular repair after
giving written informed consent. Randomisation was carried out centrally with the
use of a computer-generated permuted-block sequence and stratified according to
study center in blocks of four patients. 
The study was performed according to the principles of the Declaration of
Helsinki. The institutional review boards of all participating hospitals approved the
protocol. The corresponding author assumed full responsibility for the conduct of
the trial, had full access to all the data, and controlled the decision to publish. The
study was publicly funded, and the sponsor had no role in the study design. 
Data Collection and Follow-up 
All data were submitted to the trial-coordination center (Julius Center for Health
Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands).
Follow-up visits were scheduled 30 days and 6, 12, 18, and 24 months after the pro-
cedure. Before hospital discharge and at each follow-up visit, all patients under-
went a physical examination, which included calculation of the ankle-brachial blood-
pressure index; abdominal helical computed tomographic angiography; and
abdominal color duplex ultrasonography. In addition, patients in the endovascular
group underwent plain abdominal radiography before hospital discharge and 12
and 24 months postoperatively. 
Data acquisition was stopped on March 1, 2005, for this report. For all analy-
ses, data on patients were censored after their last follow-up visit. For the crude sur-
vival analysis, however, reports on vital status obtained at any time before the cut-
off date were also incorporated. 
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* Plus-minus values are means ±SD. FEV1 denotes forced expiratory volume in one second, and ASA
American Society of Anesthesiologists. The body-mass index is the weight in kilograms divided by the
square of the height in meters. Because of rounding not all percentages total 100.
† The Society for Vascular Surgery / International Society for Cardiovascular Surgery (SVS/ISCVS) risk-factor
score ranges for each of eight domains from 0 (no risk factors) to 3 (severe risk factors).7 Total scores can
range from 0 to 24, with higher scores indicating more risk factors. 
¥ No information was available for six patients in the open-repair group and four patients in the endovas-
cular-repair group.
Table 1
Baseline characteristics of the patients.*
Open Repair Endovascular Repair
Characteristic (N=178) (N=173)
Age –yrs 69.6±6.8 70.7±6.6
Male sex –no. (%) 161 (90.4) 161 (93.1)
Mild, moderate, or severe SVS/ISCVS risk-factor score –%†
Diabetes Mellitus 9.6 10.4
Tobacco Use 55.1 64.2
Hypertension 54.5 58.4
Hyperlipidemia 52.6 47.0
Carotid Disease 15.2 14.5
Cardiac Disease 46.6 41.0
Renal Disease 8.4 7.5
Pulmonary Disease 18.5 27.7
Sum of SVS/ISCVS risk-factor scores† 4.5±2.5 4.4±2.5
FEV1 –liters/sec 2.6±0.7 2.5±0.7
Body-mass Index 26.6±4.1 26.3±3.4
ASA class –no. (%) 
I healthy status 44 (24.7) 37 (21.4)
II mild systemic disease 110 (61.8) 122 (70.5)
III severe systemic disease 24 (13.5) 14 (8.1)
Medication use –no. (%)
Beta-adrenergic blockers 92 (51.7) 76 (43.9)
Statins 72 (41.9) 63 (37.3)
Antiplatelet agents¥ 72 (40.4) 70 (40.5)
Angiotensin-converting enzyme (ACE) inhibitors 50 (28.1) 58 (33.5)
Calcium channel blockers 32 (18.0) 30 (17.3)
Anticoagulants 27(15.2) 20 (11.6)
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End Points 
The primary end point of the trial was a composite of operative mortality and mod-
erate or severe complications, as discussed in the initial report on the results of the
trial.
2
Mortality and complications at two years were predetermined secondary end
points in the original trial design. The outcome events that we analysed were
deaths from all causes, aneurysm-related deaths, complications, and reinterven-
tions. 
The cause and exact date of death were determined by assessment of death
certificates and by contacting the physicians involved (surgeons and general prac-
titioners) and patients' relatives if necessary. Aneurysm-related death was defined
as death resulting from aneurysm rupture, graft infection, or thrombosis; any death
occurring within 30 days after the original procedure or a reintervention; or any
death occurring more than 30 days after the original procedure or a reintervention
but during the same admission. 
Complications were classified and graded according to the reporting standards
of the Ad Hoc Committee for Standardized Reporting Practices in Vascular Surgery
of the Society for Vascular Surgery/International Society for Cardiovascular
Surgery.
7,8
Three severity grades (mild, moderate, and severe) were distinguished.
Mild complications were not considered in this analysis. A reintervention was
defined as any surgical or endovascular procedure performed after the primary
aneurysm-repair procedure and related to the aneurysm or the primary procedure,
including incisional hernia repairs but exclusive of procedures involving superficial
wound complications. An outcome adjudication committee, consisting of five vascu-
lar surgeons, assessed the type and severity of each complication and reinterven-
tion in a blinded fashion and independently from each other. Disagreements were
resolved in a plenary consensus meeting. 
Statistical Analysis 
All data were analysed according to the intention-to-treat principle. Kaplan-Meier
analysis was used to analyse survival and other end points, and differences
between groups were compared with the use of the log-rank test. Cox proportion-
al-hazards regression was used to estimate hazard ratios for the analysis of reinter-
vention rates. Means (±SD) were used to describe continuous variables. Differences
between groups were compared with the use of the Mann-Whitney U test for con-
tinuous variables and Fisher's exact test for proportions. All reported P values are
two-sided and are not adjusted for multiple testing. 
10.3 Results 
Characteristics of the Patients and Treatment Assignments 
Between November 2000 and December 2003, 178 patients were randomly
assigned to undergo open repair and 173 to undergo endovascular repair. Six
patients did not undergo aneurysm repair after randomisation: four declined treat-
ment (three assigned to open repair and one to endovascular repair), one died from
a ruptured abdominal aortic aneurysm before undergoing open repair, and one
died from pneumonia before undergoing endovascular repair. There were six
crossovers: five patients who were randomly assigned to undergo open repair
underwent endovascular repair, and one patient assigned to endovascular repair
underwent open repair. Overall, the operation was started according to the ran-
domised assignment in 96.6 percent of patients (339 of 351). 
The baseline characteristics of the patients are given in Table 1. Demographic
characteristics, the prevalence of coexisting conditions, cardiovascular-risk profiles,
the distribution of American Society of Anesthesiologists risk classes, and medica-
tion use were similar in the two groups. 
The median interval between randomisation and the procedure was 39 days in
both the open-repair group (range, 4 to 260) and the endovascular-repair group
(range, 1 to 183; P=0.76); 92.6 percent of patients (325 of 351) underwent
aneurysm repair within 3 months after randomisation. The mean duration of follow-
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Figure 1
Kaplan-Meier Estimates of Survival among Patients Assigned to Undergo Open or Endovascular Aneurysm
Repair.
No. at Risk 0 months 6 months 12 monts 18 monts 24 months
Open Repair 178 164 160 133 97
Endovascular Repair 173 166 163 134 98
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up was 21 months in the open-repair group (range, 0 to 39) and 22 months in the
endovascular-repair group (range, 1 to 42). A total of 6 patients were lost to follow-
up during the first year (follow-up 98.3 percent complete) and 19 during the first
two years (follow-up 94.6 percent complete). 
Table 2
Causes of death after open and endovascular aneurysm repair
Cause of Death Preoperative* In-hospital† After Discharge All 
OR EVAR OR EVAR OR EVAR OR EVAR
N=178 N=173 N=174 N=171 N=166 N=169 N=178 N=173
No. of patients
All causes 1 1 8 2 9 17 18 20
Cardiovascular causes 0 0 2 1 3 6 5 7 
Myocardial infarction 0 0 1 1 0 1 1 2
Cardiac Arrest 0 0 1 0 2 2 3 2
Congestive Heart Failure 0 0 0 0 0 2 0 2
Stroke 0 0 0 0 1 1 1 1
AAA-related,
non-cardiovascular causes 1 0 6‡ 1!! 1¶ 1¤ 8 2 
Cancer 0 0 0 0 2 4 2 4
Other 0 1 0 0 1** 4# 1 5
Unknown 0 0 0 0 2ND 2¥ 2 2
* Two patients died before undergoing the assigned operation: one patient with pre-existent pulmonary
fibrosis assigned to undergo endovascular repair died 84 days after randomization from pulmonary infec-
tion, and one patient assigned to undergo open repair died 49 days after randomization from a ruptured
abdominal aortic aneurysm.
† In-hospital data were previously reported.2 All 10 in-hospital deaths are aneurysm-related by definition.
None of the 9 cardiovascular deaths after discharge were aneurysm-related.
‡ The causes of deaths were as follows:infection of the prosthesis; anastomotic bleeding; ischemic bowel;
intraoperative anaphylactic shock; multiple organ failure after repair of a burst abdomen, and progres-
sive dementia and refusal to eat or drink leading to respiratory insufficiency and death.
!! Bilateral pneumonia.
¶ Peritonitis resulting from an iatrogenic bowel lesion during repeated bowel operation to correct prosthetic
malalignment.
¤ Infected endograft.
** Pulmonary infection.
# Peritonitis; pulmonary embolism; respiratory insufficiency; general deterioration and old age.
ND No data were available of the cause of death.
¥ Both patients died suddenly, 33 and 41 months after the procedure. A ruptured aneurysm was consid-
ered as a possible cause of death but in neither patient was a postmortem examination performed. Both
patients had evidence of a shrinking aneurysm sac at their last (24-month) follow-up CT-scan.
Mortality 
Two years after randomisation, the cumulative survival rates were 89.6 percent for
open repair and 89.7 percent for endovascular repair, for a difference of -0.1 per-
centage point (95 percent confidence interval, -6.8 to 6.7 percentage points;
P=0.86) (Figure 1). The small but apparent survival advantage in the first year after
endovascular repair did not reach statistical significance (P=0.15) and appeared to
be based entirely on a decreased rate of in-hospital (perioperative) mortality. 
There was one preoperative death and eight in-hospital deaths in the open-repair
group and one preoperative and two in-hospital deaths in the endovascular-repair
group (Table 2). Taking into account the patients who declined treatment (three in
the open-repair group and one in the endovascular-repair group), there were 166
discharges after open repair and 169 discharges after endovascular repair. The
causes of death are listed in Table 2. After discharge, there were more deaths from
cardiovascular causes in the endovascular-repair group than in the open-repair
group (six vs. three), although this difference was not significant (P=0.50). 
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Figure 2
Kaplan-Meier Estimates of "Severe Event"-Free Survival among Patients Assigned to Undergo Open or
Endovascular Aneurysm Repair.
No. at Risk 0 months 6 months 12 monts 18 monts 24 months
Open Repair 178 150 146 121 89
Endovascular Repair 173 155 151 125 91
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There was an unexplained cluster of deaths in the endovascular-repair group
approximately one year after randomisation (Figure 1). None of these deaths were
considered to be aneurysm-related as defined in the Methods section; two of the
deaths were due to heart failure, one to acute cardiac arrest, one to stroke, and one
to aspiration pneumonia in a patient with metastatic carcinoma of the bladder. 
Aneurysm-Related Mortality 
The cumulative rates of aneurysm-related death two years after randomisation
were 5.7 percent in the open-repair group and 2.1 percent in the endovascular-
repair group, for a difference of 3.7 percentage points (95 percent confidence inter-
val, -0.5 to 7.9 percentage points; P=0.05). The difference in aneurysm-related mor-
tality at two years was based entirely on the difference in in-hospital (perioperative)
mortality. After discharge, only one additional aneurysm-related death occurred in
each group (Table 2). 
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Figure 3
Kaplan-Meier Estimates of Freedom from Reintervention among Patients Assigned to Undergo Open or
Endovascular Aneurysm Repair.
No. at Risk 0 months 6 months 12 monts 18 monts 24 months
Open Repair 178 158 153 128 93
Endovascular Repair 173 155 147 119 88
Complications 
Two years after randomisation, the rates of survival free of severe events were 80.6
percent for open repair and 83.1 percent for endovascular repair, for a difference
of -2.5 percentage points (95 percent confidence interval, -10.9 to 5.9 percentage
points; P=0.39) (Figure 2). As with the data on aneurysm-related mortality, the dif-
ference in the rate of survival free from severe events at two years was based entire-
ly on the difference in in-hospital events. The rates of survival free of moderate or
severe events two years after randomisation were 65.9 percent for open repair and
65.6 percent for endovascular repair, for a difference of 0.3 percentage point (95
percent confidence interval, -10.0 to 10.6 percentage points; P=0.88). 
There were no documented postoperative aneurysm ruptures. However, in two
patients who died after endovascular repair, the possibility of aneurysm rupture
was considered but not proved (Table 2). 
Kaplan-Meier estimates of the likelihood of freedom from reintervention are
shown in Figure 3. In the first nine months after randomisation, the rate of reinter-
vention after endovascular repair was almost three times the rate after open repair
(hazard ratio, 2.9; 95 percent confidence interval, 1.1 to 6.2; P=0.03). Thereafter,
reintervention rates were roughly parallel (hazard ratio, 1.1; 95 percent confidence
interval, 0.1 to 9.3; P=0.95). 
10.4 Discussion 
We found that by the end of the first year after randomisation, the previously
reported perioperative survival advantage of endovascular aneurysm repair over
open repair was no longer apparent.
2
Although a lower rate of aneurysm-related
death after endovascular repair did appear to be maintained during the first two
years, in terms of overall survival, this was cancelled out by excess mortality from
other causes, including cardiovascular causes, in the first two years after discharge. 
One other randomised trial, the Endovascular Aneurysm Repair (EVAR-1) trial,
has compared the results of endovascular aneurysm repair with those of open
repair.
1
Whereas the early results of the two trials were similar, the long-term
results of EVAR-1 are not yet available and thus cannot be compared with our find-
ings. 
Our results are similar to those of two recently reported retrospective, con-
trolled studies comparing endovascular and open repair.
9,10
In both studies, the
respective one-year survival rates after open and endovascular repair were approx-
imately 92 and 95 percent, and the respective two-year survival rates were approx-
imately 88 and 89 percent, all of which are very close to our findings. The rates of
aneurysm-related death two years after open and endovascular repair were 4.2
and 0.9 percent, respectively, in the study by Cao et al.,
10
as compared with 5.7 and
2.1 percent, respectively, in our study. It is possible that the prospective nature of
our study allowed for more complete detection of aneurysm-related deaths. The dif-
ference in reintervention rates between the groups in our study is also similar to
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that reported in both retrospective studies. In one study, the divergence of reinter-
vention rates did not start until after two years of follow-up,
10
whereas in our study,
there was no significant difference in reintervention rates beyond nine months after
randomisation. This variation may depend on how aggressively certain complica-
tions are addressed. 
Although our findings - and those in the other trials discussed above - suggest
that endovascular aneurysm repair may provide an early survival advantage over
conventional surgery, it appears that this advantage is lost by the end of the first
year. It is unknown whether the durability of the endovascular graft will jeopardise
long-term outcomes. Although nonrandomised, follow-up studies of patients who
have undergone aneurysm repair have failed to show a long-term advantage of
open over endovascular repair,
9,10
concerns persist, since the rates of aneurysm-
related death and reintervention after endovascular repair have been reported to
continue to increase over time.
4,11
The overall survival curves in our trial appeared
to converge in the second year after randomisation. Our 2-year data do not exclude
the possibility that these curves will actually cross, resulting in a higher rate of
death for endovascular repair than for open repair after 24 months. 
There may be two possible explanations for the convergence of survival curves
in our study. One is that patients who have survived the stress of open repair may
be somewhat less likely to die in the first few months after surgery than patients
who have undergone endovascular repair, since the latter group has not been sub-
jected to a conventional surgical procedure. In other words, the survival advantage
resulting from a less-invasive approach to aneurysm repair may largely be based
on postponing death among higher-risk patients from the perioperative period to
the subsequent months. Although patients in our trial had to be eligible to under-
go conventional open aneurysm repair before they could undergo randomisation,
the health of patients with abdominal aortic aneurysms is often seriously compro-
mised by other types of cardiovascular disease. In our study, 58 percent of the
deaths (22 of 38) were due to either cardiovascular causes or causes related to
aneurysm repair. This finding is in accordance with those of other follow-up studies
of aneurysm repair.
12,13
Another possible explanation for the convergence of survival curves is the fail-
ure of endovascular repair to prevent rupture of the aneurysm. However, endograft
failure is unlikely to occur during the first two years after implantation, and such
failure would be reflected by a convergence of the rates of aneurysm-related death
- an effect that was not found in our analysis. Although a grouping of deaths was
seen in the endovascular-repair group about one year after randomisation, the
causes of death were not related to the aneurysm. Furthermore, the apparent
grouping of these deaths was seen in a Kaplan-Meier survival analysis that meas-
ured the time from randomisation, rather than the time from the procedure, indi-
cating that this grouping of deaths was not related to the course after intervention.
Only one patient in the endovascular-repair group died of an aneurysm-related
cause (an infected endograft) after hospital discharge. Whether the rate of graft
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failure will increase with further follow-up remains to be seen. 
In patients undergoing endovascular repair, efforts should be made to maintain
the survival advantage associated with avoiding conventional surgery. This effort
may at least in part be a matter of strict risk-factor management. Beta-blockers,
antiplatelet agents, and statins were each being used in less than 50 percent of our
patients at baseline. Clearly, less-than-optimal medication was used in view of cur-
rent guidelines on risk management for patients with manifestations of atheroscle-
rosis.
14,15,16
Of course, better perioperative and postoperative management of risk
factors could also improve the results of open aneurysm repair. 
In conclusion, the two-year results of the DREAM trial indicate that the periop-
erative survival advantage with endovascular repair as compared with open repair
is limited to the first postoperative year. 
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11.1 General discussion
The natural history of an untreated abdominal aortic aneurysm (AAA) is to enlarge
and rupture. As the mortality of a ruptured AAA is high (85%), prophylactic treat-
ment seems appropriate.
1,2
On the other hand, the overall risk of rupture is low and
strongly depends on the diameter of the aneurysm.
2-4
As the risks of surgical repair
should be proportional to the risk of rupture, small AAA's may not require immedi-
ate repair. The UK-small aneurysm trial has demonstrated that 'watchful waiting' is
safe for aneurysms smaller than 5.5 cm in diameter.
5
The two most commonly used techniques for the surgical treatment of an AAA
are conventional open repair (OR) and endovascular repair (EVAR). Operative mor-
tality and morbidity rates of OR are significant. A meta-analysis including 37.654
procedures reported a mortality rate between 3.5% and 8.2%.
6
The durability of
OR, established with long-term follow-up studies, is excellent and there is little or no
requirement for long-term surveillance.
7-9
EVAR is a less invasive alternative to OR.
It was designed as a treatment for patients who were unfit for OR.
10
While initial
results were promising, disadvantages of EVAR soon became clear. Despite this, the
less-invasive nature of the procedure led to widespread application of EVAR for
standard risk patients, emphasizing the need for a head to head randomised com-
parison between OR and EVAR.
In a retrospective study (chapter 2), we assessed the impact of EVAR on mortality
of aneurysm repair in one decade (1991-2000). This population-based study
showed that the introduction of EVAR (1994) had an impact on the over-all in-hos-
pital mortality, even with only a small percentage of patients being treated by
endovascular techniques. In the multivariate analysis, age and endovascular repair
were the most important independent predictors of in-hospital mortality. This study
had several limitations. In the first years after the introduction of EVAR, it was used
only in patients meeting the strict anatomic selection criteria and protocol inclusion
criteria for the specific devices used. This resulted in selection bias as only patients
with easier aneurysms underwent EVAR, possibly leading to a slightly higher mor-
tality rate in the contemporary OR patients and a lower mortality rate in the EVAR
group. Conversely, EVAR was used mostly in older patients unfit for OR, which
would have the opposite effect on operative mortality. Furthermore, only in-hospi-
tal mortality was assessed. In general, length of stay is much shorter after EVAR
than after OR. So, problems occurring after discharge may have been missed in the
EVAR group. The above mentioned shortcomings of our population-based study
preclude a valid comparison of EVAR and OR. However, they did stress the need for
further research.
Three registries, EUROSTAR, Lifeline Registry, and RETA, have monitored the
progress and development of EVAR over the past 8 years.
11-13
The data of these
registries have shown a relatively high 30-day mortality rate after EVAR, varying
between 2.9% and 3.1%. A systematic review including 9 studies found a similar
mortality rate for EVAR (3%).
14
However, none of these studies were randomised,
prohibiting an unbiased assessment of benefits and risks of EVAR and OR. This
underlined the need for a randomised trial.
Worldwide, four randomised trials were set-up: the EVAR-1 (endovascular
aneurysm repair) trial in the United Kingdom, the DREAM (Dutch randomised
endovascular aneurysm management) trial in the Netherlands, the OVER (open
versus endovascular repair) trial in the USA, and the ACE-trial (the Anévrisme de
l'aorte abdominale: Chirurgie versus Endoprothèse) in France. 
The OVER and ACE trial will be recruiting patients until approximately 2008.
The operative mortality results of the EVAR-1 trial were published almost simulta-
neously with those of the DREAM-trial (chapter 5). As described in chapter 9, both
trials show similar results. The EVAR-1 trial reported a significant reduction in in-
hospital mortality with EVAR versus OR, from 6.0 to 1.6 % (p=0.007).
15
In our trial,
these numbers were 4.6% and 1.2%, respectively.
16
The agreement between the
two trials supports the conclusion that EVAR is associated with reduced operative
mortality and morbidity rates and shorter hospital stay in comparison to OR. These
findings compare well with those available in the literature, but there are some dif-
ferences. 
Before the introduction of EVAR, the operative mortality rate of AAA repair in
population-based studies was roughly 8%.
6
This is much higher than the 4.6% we
have found in our study. However, it is likely that more patients with a high opera-
tive risk were treated with OR, as EVAR was not available at that time. The opera-
tive mortality rate after EVAR was also lower in our study than that reported by the
registries.
11;12
The results of the DREAM-trial and EVAR-1 trial also compare well
with the results of a nationwide comparison in the USA, reporting mortality rates
of around 4% for OR and 1% for EVAR.
17,18
With the increasing use of EVAR, it is hard to predict whether the overall pop-
ulation-based mortality will decrease. As shown in chapter 2, the introduction of
EVAR had an impact on the overall mortality, but in that specific time-period EVAR
was only used in a highly selected population. In our population-based study we
observed an increase in the EVAR related mortality by the end of the decade, prob-
ably because of less strict criteria used for patient selection.
Before answering the main question of this thesis –which treatment is better: EVAR
or OR?–, several aspects need to be addressed.
First, the EVAR-1 trial and the DREAM-trial were performed in a patient popu-
lation suitable for both treatments, i.e. patients with an acceptable operative risk
and a relative easy anatomy. Therefore, these results are not applicable for patients
unfit for conventional AAA repair and likewise they cannot be generalised to
patients who are not suitable for EVAR. Consequently, the results only apply to a
patient population considered fit for either procedure.
Second, a reduction in operative morbidity and mortality does not result neces-
sarily in an overall benefit of EVAR over OR. A new, less invasive therapy can be
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expected to reduce the number of procedural complications, irrespective of that
therapy being effective or not. An evaluation of the long-term risk of graft compli-
cations and aneurysm rupture is mandatory before answering the question about
the best treatment. As shown in chapter 10, in the first 9 months after randomisa-
tion, the rate of reinterventions was 3 times higher after EVAR than after OR.
However, thereafter the reintervention rates were roughly parallel. This reinterven-
tion rate is also similar to that reported in 2 retrospective studies.
19,20
The registries
for AAA repair have reported a failure rate for endoprosthesis of 3% per year (1%
rupture plus 2% conversion to OR), and a secondary intervention rate of 10%.
21
Whether the rate of graft failure will change over time remains to be seen. Non-ran-
domised follow-up studies have reported a continuous increase in reintervention
rates over time.
22-24
As endovascular repair is rapidly evolving, newer devices may
require less reinterventions than with the devices used in the period 2000-2003.
Besides this, longer follow-up studies may justify higher thresholds for reinterven-
tion.
Third, besides the questions of durability, long-term survival needs to be
assessed. Two earlier studies have shown a 5-year survival rate of about 70% after
OR.
25,26
Some studies have shown similar 5-year survival rates after EVAR. However,
these results are obtained from highly selected patient populations.
23,27
Both, the
DREAM trial and the EVAR-1 trial have shown substantial reductions in 30-day
postoperative mortality with EVAR (chapter 5 and 9). However, as shown in chap-
ter 8 and 10, this survival advantage was lost by the end of the first year. The over-
all survival curves appeared to converge one year after randomisation. This did not
exclude the possibility of these curves actually crossing, EVAR to be detrimental in
the long-term. The EVAR-1 trial also reported the initial survival advantage with
EVAR to be lost after about two years.
28
Thereafter, the survival curves ran parallel
up to four years after randomisation but longer-term data is also lacking. In the
DREAM-ON trial the long-term survival (up to seven years) will be analysed. 
Besides the issues on the long-term results, some other factors need to be dis-
cussed before coming to conclusions about the best treatment. 
Age is a well-known predictor of mortality after AAA repair (chapter 2), with an
increasing risk at advanced age. While EVAR may be preferable in older patients,
the results of OR and EVAR may be equivalent in relatively young patients. In older
patients, the perspective of long-term survival may not be sufficient to counterbal-
ance the competing risks of cardiovascular morbidity and mortality after OR. In a
younger patient population, sexual dysfunction due to the operation may need to
be considered in choosing between EVAR and OR. As shown in chapter 7, the sex-
ual dysfunction rate in the older patient is already high at the outset, rendering this
issue less important in many of these patients. The DREAM-trial was not powered
to detect differences in this respect. The number of young patients included in the
study on sexual function was limited.
In chapter 6, we assessed quality of life (QoL) in the first postoperative year. We
concluded that there was a small yet significant QoL advantage of EVAR over OR
in the early postoperative period. However, this advantage did not seem to sustain
itself one year after surgery. The uncertainty of the durability of EVAR and the rel-
atively high reintervention rate may have had a negative effect on QoL. However,
the QoL after EVAR at one year was similar to that preoperatively. This would imply
that uncertainty and reinterventions after EVAR did not affect QoL. The same
results were found in two randomised trials comparing QoL after elective EVAR and
OR and in a prospective controlled trial by Ballard et al.
28-30
In chapter 8, QoL is
assessed in a larger subgroup of the DREAM-trial, demonstrating no difference in
quality adjusted life years one year after surgery. As the impact of a treatment on
QoL is of utmost importance from the patient's perspective, QoL studies with longer
follow-up are needed to evaluate the differences in QoL on the long-term. The
DREAM-trial cohort will be followed for several years to provide an answer to this
question.
Two other important issues need consideration: the costs and cost-effectiveness
of OR and EVAR. In chapter 8, we found that EVAR tended to result in slightly longer
event free survival, but against higher costs. However in terms of QALYs, OR
appeared superior, albeit marginally. From a health economic perspective, we con-
cluded that OR is preferable. The same conclusion was drawn from the results of
the EVAR-1 trial.
28
The size-threshold to treat an AAA has always been a debate but varies
between 5.0 and 5.5cm in diameter. The UK small aneurysm trial compared sur-
veillance with early surgery and demonstrated that below 5.5 cm risks of surgery
do not counterbalance the risk of rupture unless the aneurysm shows rapid enlarge-
ment or causes symptoms.
5
The question arises, whether this threshold should be
lowered for patients suitable for endovascular repair as the risks of surgery are
reduced. Smaller AAA's are more frequently candidates for endovascular repair due
to more favourable anatomy.
31
The complication rate after EVAR of small
aneurysms is also lower than that of larger ones.
32
So with lowering the threshold
for repair, more patients could be offered EVAR with a lower complication rate. On
the other hand, the risk of rupture of an AAA with a diameter between 4.0 and 5.5
cm is extremely low (about 1%) and probably still does not counterbalance the
reduced risk after EVAR.
5,33
Moreover, patients with smaller aneurysms tend to be
younger and may very be able to withstand the 'stress' of OR. Accordingly, the
results of OR of small AAA's are probably better also. 
The development of branched and fenestrated endovascular prostheses prom-
ises to enlarge the anatomic applicability of EVAR. These grafts are customised to
the patient's anatomy. Recent studies have shown that these new techniques, with
graft material incorporating the visceral arteries, are technically feasible.
34,35
However, only short-term results of small numbers of patients are available at this
time.
New techniques like 'small incision' surgery and laparoscopic AAA repair have
been developed. To date, only a small number of patients have been treated with
these techniques. Available studies show that laparoscopic AAA repair is feasible
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and initial results are promising.
36-38
In the future, they may be offered as a mini-
mally invasive alternative for patients whose anatomy is not suitable for EVAR and
who are clinically unfit for OR. However, these new techniques have a long learn-
ing curve and further evaluation, including a randomised trial, is required to inves-
tigate the true benefits compared to OR and EVAR.
When taken together, the results of the DREAM-trial suggest that EVAR is
preferable to OR in the short-term. The operative mortality and severe morbidity is
lower after EVAR. There is a quality of life advantage and the effect of EVAR on sex-
ual function is reduced. However, all these advantages of EVAR apply only in the
early postoperative period, as they are no longer apparent after one year. So EVAR
is beneficial as compared with OR, as it delays death, increasing the area under
the survival curve. Although this difference is minimal, the relevance of a reduction
in perioperative risk should not be underestimated from a patient's perspective. 
Longer follow-up is essential to evaluate the durability of EVAR. In the DREAM-
ON trial, long-term survival results will be studied, including the costs and quality
of life on the long-term.
After EVAR, secondary interventions are required in about 10-25% of patients
in the first 4 years after EVAR.
21,28,39
Most of these interventions will be endovascu-
lar and therefore will not substantially affect the mortality rate. However, they will
have an impact on the already unfavourable cost-effectiveness for EVAR.
In case EVAR and OR are both options for a specific patient, results of the
DREAM-trial suggest that age should be taken into consideration. For the older
patients, short-term benefits may be more valuable and therefore EVAR with a pos-
sibly lower durability may be acceptable. Note, however, that particularly in older
patients competing risks should be taken into account as cardiovascular morbidity
and mortality may impede them to 'enjoy' a repaired AAA. Additional research
should address eligibility criteria for AAA repair as patients at considerable cardio-
vascular risk are not likely experience any real benefit from elective surgery. On the
other hand, relatively young patients with good surgical risk and many years to live
may end up suffering long-term morbidity more than EVAR can avoid perioperative-
ly. It seems that long-term results of the trials are particularly relevant for this sub-
group of patients.
11.2 Conclusion
In conclusion, the results of the DREAM-trial provide justification for offering both
EVAR and OR to patients eligible for elective AAA repair. However, more accurate
selection criteria need to be established distinguishing patients who will benefit
most from EVAR from those in whom this more expensive treatment will have no
apparent advantage.
For EVAR to become the treatment of first choice in all eligible patients, it must
be proven durable, allowing minimisation of follow-up. Moreover, the initial survival
benefit of EVAR over OR should be amplified by using better selection criteria or at
least be maintained, possibly by applying rigorous and effective atherosclerosis risk
factor reduction strategies.
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SUMMARY
Elective treatment of abdominal aortic aneurysms (AAA) has been performed for
more than 50 years. For more than 4 decades open repair (OR) has been the gold
standard of aneurysm treatment. The short- and long-term results of OR are well
known; mortality may be rather high (4-8%), but the long-term results are excellent
and there is little or no requirement for follow-up.
In 1991 endovascular aneurysm repair (EVAR) was introduced as a less invasive
alternative for patients unfit for open aneurysm repair. It was expected to have
lower morbidity and mortality rates than OR. During the last decade of the 20th
century, the feasibility of EVAR has been demonstrated, but the effectiveness as
compared to OR remained unclear. Initial results appeared promising, yet, with
more results of EVAR becoming available, also specific complications and disadvan-
tages of EVAR became clear. 
Although from its beginning EVAR has been used in patients unfit for OR, very
soon it was considered as treatment of first choice by many surgeons. This notion
emerged despite a lack of convincing evidence demonstrating EVAR to be superior
to conventional open repair. Several comparative studies had been published, but
no randomised trials were available.
The key question of this thesis is: 'which is better for patients suitable for both treat-
ments: Endovascular or open repair?
In chapter 2 the impact of EVAR on nation-wide in-hospital mortality of non-rup-
tured AAA repair over the past decade is reported retrospectively. The in-hospital
mortality of non-ruptured AAA repair in 16,446 patients in the 10-year period from
1991 to 2000 was 7.3% (6.2-8.2%). In the 15,589 (95%) patients that underwent
conventional treatment, in-hospital mortality was 7.6% (7.0-8.1%), whereas in the
endovascular group it was 1.9% (0.6-3.5%). Despite the obvious limitations of a
national registry based study the introduction of endovascular aneurysm repair
appears to have had a small but significant impact on in-hospital mortality follow-
ing AAA repair. 
In chapter 3 the design of the Dutch Randomised Endovascular Aneurysm
Management (DREAM)-trial is described. The DREAM-trial is a randomised multi-
center trial enrolling patients eligible for elective treatment of infrarenal AAA's. The
cost-effectiveness of EVAR is compared with that of OR, in patients that are
considered suitable for both treatments. The primary endpoint is combined opera-
tive mortality and morbidity. Secondary endpoints and additional assessments
include event free survival, quality of life, length of hospital stay and costs. 
In chapter 4 the principle of continuous monitoring of safety is described. In many
randomised trials, an interim analysis based on the primary endpoint is foreseen,
for example halfway during patient inclusion. In surgical trials, interim analyses are
typically based on primary endpoints such as 30-day mortality or morbidity.
However, specific disorders or procedure-related complications may occur any time.
Accordingly, continuous monitoring of safety, evoking a blinded interim analysis
every time a serious event occurs, should be considered. This would enable ade-
quate action to be taken as soon as the data reveal a relevant and significant dif-
ference in incident adverse events. A clinically relevant difference in adverse events
is thus detected in a timely fashion, which will ensure the safety of potential partici-
pants not yet randomised.
In chapter 5, the primary endpoint of the DREAM-trial (the operative morbidity and
mortality) is reported. 345 Patients with an AAA of at least 5 cm were randomised:
174 patients in the OR group and 171 in the EVAR group. The operative mortality
rate was 4.6 percent in the OR group and 1.2 percent in the EVAR group. The com-
bined rate of operative mortality and severe complications was 9.8 percent in the
OR group and 4.7 percent in the EVAR group. We concluded that EVAR might be
preferable to OR in patients who have an AAA that is at least 5 cm in diameter.
Long-term follow-up is needed to determine whether this advantage is sustained.
In chapter 6 quality of life (QoL) in the first postoperative year is compared after
OR and EVAR. QoL questionnaires (SF-36 and EuroQoL-5D) were sent to all patients
preoperatively and at five time points in the first postoperative year. After 3 weeks,
both groups showed a decrease on the EuroQoL-5D, in the OR group more domains
of the SF-36 had decreased than in the EVAR group (6 versus 5). At 6 weeks, the
EuroQoL-5D had recovered to baseline in the OR group and the decreased domains
of the SF-36 had partially recovered. In the EVAR group the EuroQoL-5D and three
of the five decreased SF-36 domains, had returned to baseline. From 6 months on,
the OR group reported a significantly higher score on the EuroQoL-5D than the
EVAR group. In summary, in the early postoperative period there is a small, yet sig-
nificant QoL advantage for EVAR compared to OR. At 6 months and beyond,
patients reported better QoL after OR than after EVAR. 
In chapter 7, the impact of OR and EVAR on the sexual function in the first postop-
erative year is studied. Together with the QoL questionnaires 5 questions on sexu-
al function were sent to the patients. The preoperative reported sexual dysfunction
rate was already high in both groups (66% for OR, 74% for EVAR). Surgery had a
clear impact on sexual dysfunction: both the percentage of patients reporting sex-
ual dysfunction as well as the magnitude of sexual dysfunction increased in both
groups. The latter was more pronounced in the OR group. The sexual dysfunction
had recovered to baseline after 6 weeks in the EVAR group and after 3 months in
the OR group. We concluded that EVAR and open elective AAA repair both have
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an impact on sexual function in the early postoperative period. After EVAR, recov-
ery to preoperative levels is faster than after open repair, but at 3 months, sexual
dysfunction levels are similar in both groups.
Chapter 8 describes the costs and cost effectiveness of OR and EVAR in the first
year after surgery. There was no difference in survival or severe events between OR
and EVAR at one year. EVAR was associated with €4.300 increase in direct costs
per patient (€18.179 versus €13.886) and 0.72 QALY's of as compared with 0.73
after OR. For event free survival the majority of the bootstrap estimates indicated
that EVAR tended to have favourable health outcomes. Thus, only marginal short-
term health gain may be expected at high costs
In chapter 9, a meta-analysis on the early outcomes of the two available ran-
domised trials comparing elective AAA repair is performed. The resulting mortality
risk difference -0.04 (-0.07; -0.02, P<0.001) and mortality risk ratio 0.44 (0.27; 0.70,
P<0.001) favoured endovascular repair. In conclusion, pooling of the results of two
randomised studies enhances the conclusion that EVAR produces better early
results than OR.
In chapter 10, the mid-term results of the DREAM-trial are described. Two years
after randomisation, the cumulative survival rates were 89.6 percent for OR and
89.7 percent for EVAR. The cumulative rates of aneurysm-related death were 5.7
percent for OR and 2.1 percent for EVAR. This advantage of EVAR over OR was
entirely accounted for by events occurring in the perioperative period, with no sig-
nificant difference in subsequent aneurysm-related mortality. The rate of survival
free of moderate or severe complications was also similar in the two groups at two
years (65.9 percent for OR and 65.6 percent for EVAR. In conclusion, the perioper-
ative survival advantage with endovascular repair as compared with open repair is
not sustained after the first postoperative year. 
Conclusions
From a patient's perspective, EVAR appears to have several albeit limited advan-
tages over OR for first postoperative months. The operative mortality and severe
morbidity are substantially lower and the impact on quality of life and sexual dys-
function is smaller. However, within the first postoperative year these advantages
are lost. In addition, EVAR is more expensive and in terms of life years gained not
cost-effective. Currently, life-long surveillance is advised after EVAR, whereas for OR
no significant follow-up is recommended. This will only further worsen the already
unfavourable cost-effectiveness of EVAR.
In conclusion, the results of the DREAM-trial provide justification for offering both
EVAR and OR to patients eligible for elective AAA repair. However, more accurate
selection criteria need to be established distinguishing patients who will benefit
most from EVAR from those in whom this more expensive treatment will have no
apparent advantage.
For EVAR to become the treatment of first choice in all eligible patients, it must
be proven durable, allowing minimisation of follow-up. Moreover, the initial survival
benefit of EVAR over OR should be amplified by using better selection criteria or at
least be maintained, possibly by applying rigorous and effective atherosclerosis risk
factor reduction strategies.
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SAMENVATTING
De electieve behandeling van een aneurysma van de aorta abdominalis (AAA)
wordt al ruim 50 jaar uitgevoerd. Meer dan 4 decaden werd de conventionele
(open) aneurysma behandeling (OR) als gouden standaard beschouwd. De korte en
lange termijn resultaten van deze behandeling zijn bekend: de operatieve mortali-
teit is vrij hoog (4-8%), maar de lange termijn resultaten zijn uitstekend en er is in
principe geen follow-up nodig.
In 1991 werd de endovasculaire AAA behandeling (EVAR) geïntroduceerd als
een minder invasieve behandeling voor patiënten die ongeschikt waren voor de
conventionele behandeling. De verwachting was dat EVAR een lagere morbiditeit
en mortaliteit zou hebben. In de laatste decade van de 20e eeuw is de toepas-
baarheid van EVAR aangetoond of het echter ook even effectief is als OR in de
exclusie van het AAA was onduidelijk. De eerste resultaten van EVAR waren veel
belovend. Naarmate er meer resultaten van EVAR bekend werden, kwamen er ook
complicaties en nadelen aan het licht.
Hoewel EVAR aanvankelijk was bedoeld voor patiënten die ongeschikt waren
voor OR, werd het door veel chirurgen al snel beschouwd als behandeling van
eerste keus. Echter, overtuigend bewijs dat aantoonde dat EVAR beter was dan OR
was er niet. Diverse vergelijkende studies waren gepubliceerd, maar geen geran-
domiseerde studies.
De centrale vraag van dit proefschrift is: 'welke behandeling is beter voor patiënten
die geschikt zijn voor beide behandelingen: de endovasculaire of conventionele
behandeling?'.
In hoofdstuk 2 wordt de invloed van EVAR op de landelijke in-ziekenhuis mortaliteit
van de behandeling van het niet-geruptureerde AAA in de laatste decade
beschreven. De in-ziekenhuis mortaliteit van de niet-geruptureerde AAA behan-
deling in 16,446 patiënten over een periode van 10 jaar (1991-2000) was 7.3% (6.2-
8.2%). In de 15,589 (95%) patiënten die de conventionele behandeling ondergin-
gen was de in-ziekenhuis mortaliteit 7.6% (7.0-8.1%), terwijl in de endovasculaire
groep deze 1.9% (0.6-3.5%) was. Met de beperkingen van een nationale registratie
in acht nemend, lijkt de introductie van EVAR een klein maar significant effect te
hebben op de in-ziekenhuis mortaliteit na AAA behandeling. 
In hoofdstuk 3 wordt het design van de Dutch Randomised Endovascular Aneurysm
Management (DREAM)-trial beschreven. De DREAM-trial is een gerandomiseerde
multicenter studie, waarin patiënten worden geïncludeerd die in aanmerking
komen voor electieve behandeling van een infrarenaal AAA. De kosteneffectiviteit
van EVAR wordt vergeleken met die van OR in patiënten die geschikt zijn voor beide
behandelingen. Het primaire eindpunt is de gecombineerde operatieve mortaliteit
en morbiditeit. Secondaire eindpunten zijn complicatie vrije overleving, kwaliteit
van leven, opnameduur en kosten. 
Hoofdstuk 4 beschrijft het principe van continue bewaking van veiligheid. In veel
gerandomiseerde studies wordt een interim analyse gedaan van het primaire eind-
punt, meestel halverwege de inclusie. In chirurgische trials wordt de interim
analyse gebaseerd op het primaire eindpunt, zoals 30-dagen mortaliteit of mor-
biditeit. Echter, specifieke problemen of procedure gerelateerde complicaties kun-
nen op ieder tijdstip optreden. Om die reden moet continue bewaking van de vei-
ligheid overwogen worden, met een geblindeerde interim analyse op het moment
dat er een complicatie optreedt. Dit maakt het mogelijk om, op het moment dat de
data een relevant en significant verschil in complicaties aantonen, de trial te stop-
pen. Een klinisch relevant verschil in complicaties wordt dus tijdig gedetecteerd, het-
geen de veiligheid van nog niet gerandomiseerde patiënten verzekert.
In hoofdstuk 5 wordt het primaire eindpunt van de DREAM-trial (operatieve mor-
biditeit en mortaliteit) beschreven. 345 Patiënten met een AAA van tenminste 5 cm
werden gerandomiseerd: 174 patiënten in de OR groep en 171 in de EVAR groep.
De operatieve mortaliteit was 4.6% in de OR groep en 1.2% in de EVAR groep. De
gecombineerde frequentie van operatieve mortaliteit plus ernstige complicaties
was 9,8% in de OR-groep en 4,7% in de EVAR-groep We concludeerden dat EVAR
de voorkeur heeft boven OR in patiënten met een AAA van tenminste 5 cm.
Langduriger follow-up is noodzakelijk om te kunnen vaststellen of dit voordeel ook
op langere termijn blijft bestaan. 
In hoofdstuk 6 wordt de kwaliteit van leven (QoL) in het eerste postoperatieve jaar
vergeleken na OR en EVAR. QoL-vragenlijsten (SF-36 en EQ-5D) werden naar alle
patiënten gestuurd, preoperatief en op 5 tijdstippen in het eerste jaar. Na 3 weken
lieten beide groepen een afname zien in de EQ-5D scores. In de OR groep nam de
score op meer domeinen van de SF-36 af dan in de EVAR groep (6 versus 5). Na 6
weken waren de EQ-5D scores terug naar de uitgangswaarde in de OR groep en
de verminderde domeinen van de SF-36 waren gedeeltelijk hersteld. In de EVAR
groep waren de EQ-5D en 3 van de 5 verminderde domeinen van de SF-36 volledig
hersteld. Vanaf 6 maanden rapporteerde de OR groep significant betere scores op
de EQ-5D dan de EVAR groep. Samenvattend, in de vroege postoperatieve periode
is er klein maar significant kwaliteit van leven voordeel voor EVAR in vergelijking tot
OR. Vanaf 6 maanden rapporteerden patiënten na de conventionele AAA behan-
deling een betere kwaliteit van leven dan na EVAR. 
In hoofdstuk 7 wordt de invloed van OR en EVAR op de seksuele functie in het
eerste postoperatieve jaar beschreven. Samen met de QoL vragenlijsten werden 5
vragen over seksuele functie naar de patiënten gestuurd. Preoperatief was het per-
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centage seksuele dysfunctie al hoog in beide groepen (66% voor OR, 74% voor
EVAR). De operatie had duidelijk invloed op de seksuele dysfunctie: zowel het per-
centage patienten met seksuele dysfunctie, als de ernst van de seksuele dysfunctie
namen toe. De laatste was meer uitgesproken in de OR groep. De seksuele dysfunc-
tie had zich hersteld tot de uitgangswaarde na 6 weken in de EVAR groep en na 3
maanden in de OR groep. Concluderend, EVAR en OR hebben beide invloed op de
seksuele functie in de eerste maanden na de operatie. Na EVAR is het herstel naar
de uitgangswaarde sneller dan na OR, maar na 3 maanden is de mate van sek-
suele dysfunctie in beide groepen even groot.
Hoofdstuk 8 beschrijft de kosten en de kosteneffectiviteit van OR en EVAR in het
eerste postoperatieve jaar. Er werd geen verschil gevonden tussen beide groepen
in overleving of ernstige complicaties op 1 jaar. EVAR was geassocieerd met
€4.300 extra kosten per patiënt (€18.179 versus €13.886) en 0.72 QALY's in
vergelijking tot 0.73 na OR. In de meerderheid van de bootstrap schattingen voor
complicatie vrije overleving had EVAR gunstigere gezondheid uitkomsten. Er is dus
een marginale gezondheidswinst op de korte termijn echter tegen hoge kosten.
EVAR kan op dit moment niet beschouwd worden als efficiënt alternatief voor OR. 
Hoofdstuk 9 beschrijft een meta-analyse van de vroege uitkomsten van de 2
beschikbare gerandomiseerde studies die de electieve AAA behandeling
vergelijken. Het mortaliteitsrisico verschil van -0.004 (-0.07 ; -0.02, P<0.001) en de
moraliteitsrisico ratio van 0.44 (0.27; 0.70, p<0.001) zijn in het voordeel van EVAR.
Concluderend, de samengevoegde resultaten van 2 gerandomiseerde studies
ondersteunen de conclusie dat vroege resultaten van EVAR beter zijn dan van OR.
In hoofdstuk 10 worden de middenlange termijn resultaten van de DREAM-trial
beschreven. Twee jaar na randomisatie waren de cumulatieve overlevingsfrequen-
ties 89.6% voor OR en 89.7% voor EVAR. De cumulatieve frequenties voor aneurys-
ma gerelateerde sterfte waren 5.7% voor OR en 2.1% voor EVAR. Dit voordeel van
EVAR boven OR wordt volledig verklaard door de complicaties die zijn opgetreden
in  de peri-operative periode, daarna bestaat er geen verschil meer in aneurysma
gerelateerde sterfte. Het percentage overleving zonder matig-ernstige of ernstige
complicaties was gelijk in beide groepen na 2 jaar (65.9% voor OR en 65.6% voor
EVAR). Concluderend, het peri-operatieve overlevingsvoordeel van EVAR in
vergelijking met OR blijft niet gehandhaafd na het eerste postoperatieve jaar. 
Conclusies
Vanuit het perspectief van de patiënt heeft EVAR in de eerste postoperatieve maan-
den diverse voordelen ten opzichte van OR. De operatieve sterfte en ernstige mor-
biditeit zijn aanzienlijk lager en de negatieve invloed op de kwaliteit van leven en
het seksueel functioneren is kleiner. Dit voordeel is echter binnen het eerste post-
operatieve jaar verdwenen. Daarnaast is EVAR duurder en in termen van gewon-
nen levensjaren niet kosteneffectief. Momenteel wordt levenslange follow-up ge-
adviseerd na EVAR, terwijl dit na OR eigenlijk niet nodig is. Dit zal de toch al ongun-
stige kosteneffectiviteit niet positief beïnvloeden.
Concluderend, de resultaten van de DREAM-trial zijn een rechtvaardiging om
zowel EVAR als OR aan te bieden aan patiënten die geschikt zijn voor electieve AAA
behandeling. Echter, meer accurate selectie criteria moeten worden ontwikkeld om
die patiënten te kunnen onderscheiden die het meeste voordeel hebben bij EVAR
van die patiënten bij wie deze duurdere behandeling geen duidelijk voordeel
oplevert. Om de behandeling van eerste keus te worden in alle geschikte patiënten,
zal EVAR bewezen duurzaam moeten zijn zodat de follow-up geminimaliseerd kan
worden. Daarnaast zal het initiële overlevingsvoordeel van EVAR moeten worden
versterkt door toepassing van betere selectie criteria of zal het op zijn minst
behouden moeten worden, mogelijk door toepassing van rigoureuze en effectieve
strategieën om atherosclerose risicofactoren te reduceren.
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The members of the Dutch Randomised Endovascular Aneurysm Management Trial
Group were as follows: 
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D.E. Grobbee, J.D. Blankensteijn, J. Buth, P.M. Pattynama, E.L.G. Verhoeven,
A.E. van Voorthuisen, and A.A.A. Bak.
Executive committee
J.D. Blankensteijn, M. Prinssen, M.R.H.M. van Sambeek, E.L.G. Verhoeven, J. Buth,
Ph.W.M. Cuypers, R. Balm, E. Buskens, and D.E. Grobbee.
Data monitoring and ethics committee
M.G. Hunink , J.M. van Engelshoven,  M.J.H.M. Jacobs, and B.A.J.M. de Mol.
Site & Device Selection Committee 
J.H. van Bockel, R. Balm, J. Reekers, X. Tielbeek, E.L.G. Verhoeven, and W. Wisselink.
Data management and datamonitoring
N. Boekema, and I. Sikking
Outcome Adjudication Committee 
M. Prinssen, R. Balm, J. Buth, M.R.H.M. van Sambeek, E.L.G. Verhoeven, and
J.D. Blankensteijn.
Data analysis
J.D. Blankensteijn, M. Prinssen, and E. Buskens.
Clinical centers (number of patients randomised)
The Netherlands
Catharina Hospital Eindhoven – J. Buth, A.V. Tielbeek (N=94);
University Medical Center Utrecht – J.D. Blankensteijn (N=35);
Academic Medical Center Amsterdam – R. Balm, J.A. Reekers (N=32);
Erasmus Medical Center Rotterdam – M.R.H.M. van Sambeek, P. Pattynama (N=30);
University Hospital Groningen – ELG Verhoeven, T. Prins (N=27);
St. Franciscus Gasthuis Rotterdam – A.C. van der Ham, J.J.I.M. van der Velden (N=27);
Rijnstate Hospital Arnhem – S.M.M. van Sterkenburg, G.B. ten Haken (N=14);
Leyenburg Hospital 's Gravenhage – C.M.A. Bruijninckx, H. van Overhagen (N=9);
Albert Schweitzer Hospital Dordrecht – R.P. Tutein Nolthenius, T.R. Hendriksz (N=8);
Atrium Medical Center Heerlen – J.A.W. Teijink, H.F. Odink (N=8);
MC Rijnmond-Zuid Rotterdam – A.A.E.A. de Smet, D. Vroegindeweij (N=7);
Jeroen Bosch Hospital den Bosch – R.M.M. van Loenhout, M.J. Rutten (N=7);
St. Elisabeth Hospital Tilburg – J.F. Hamming, L.E.H. Lampmann (N=5);
Maxima Medical Center Veldhoven – M.H.M. Bender, H. Pasmans (N=5);
OLVG, Amsterdam – A.C. Vahl, C. de Vries (N=5);
Meander Medical Center Amersfoort – A.J.C. Mackaay (N=4);
Vlietland Hospital Schiedam – L.M.C. van Dortmont (N=4);
Radboud University Nijmegen Medical Centre – D. van der Vliet;  L.. Schultze Kool (N=4);
Martini Hospital  Groningen – J.H.B. Boomsma, H.R. van Dop (N=3);
MC Haaglanden 's Gravenhage – J.C.A. de Mol van Otterloo, T.P.W. de Rooij (N=3);
Hospital Bernhoven Oss – T.M. Smits (N=3);
Oosterschelde Hospital Goes – E.N. Yilmaz (N=3);
VU Medical Center Amsterdam – W. Wisselink, F.G. van den Berg (N=2);
Leiden University Medical Center – M.J.T. Visser, E. van der Linden (N=1);
University Medical Center Maastricht – G.W.H. Schurink, M. de Haan (N=1);
Bronovo Hospital 's Gravenhage – H.J. Smeets (N=1).
Belgium
St Jozef Hospital Turnhout – P. Stabel (N=4);
St. Trudo Hospital St. Truiden – F. van Elst (N=3);
University Hospital Antwerpen – J. Poniewierski (N=1);
University Medical Center Gent – F.E.G. Vermassen (N=1).
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blij dat ik daar deel van heb mogen uitmaken. Ik blijf me nog steeds verbazen over
jouw wetenschappelijke kennis en doorzettingsvermogen. Dank voor alles wat je
me geleerd hebt en alle mogelijkheden die je me hebt gegeven.
Prof. dr. D.E. Grobbee, beste Rick, dank dat DREAM heeft mogen profiteren van de
professionaliteit van het Julius Centrum en dat je mij hebt gefaciliteerd door er op
cruciale momenten voor me te zijn.
Dr. E. Buskens, beste Erik, we hebben heel wat uurtjes samen nagedacht over aller-
lei (voor mij) ingewikkelde analyses. Gelukkig zijn we er altijd uitgekomen. Dank
voor je uitleg en begeleiding.
Dr. A.A.A. Bak, beste Annette, met deze initialen was je uiteraard de meest geschik-
te persoon als projectmanager van de DREAM-trial. Dank voor je objectieve en kri-
tische kijk tijdens alle MT-vergaderingen.
Nicole Boekema, je bent een super datamanager. Geweldig dat dingen die voor mij
bijna onmogelijk leken, voor jou 'appeltje-eitje' waren. Naast een goede collega ben
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geval goed, dus dat belooft wat! 
Dr. I. van der Tweel, beste Ingeborg, als het echt moeilijk werd dan hadden we jou
nodig. Dank voor je geduld waarmee je de meest ingewikkelde statistiek hebt uit-
gelegd.
Alle andere medewerkers van het Julius Centrum die zich hebben ingezet voor de
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Alle chirurgen en radiologen die hebben meegewerkt aan de DREAM-trial, dank
voor jullie inzet en doorzettingsvermogen. Zonder jullie was het nooit gelukt.
De leden van de Trial Steering Committee, de Data Monitoring and Ethics
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het in goede banen leiden van de DREAM-trial.
De leden van de beoordelingscommissie, bestaande uit prof. dr. R.P. Bleichrodt,
prof. dr. J.O. Barentsz, dr. R. Laheij, prof. dr. H. van Urk en prof. dr. W. Wisselink wil
ik graag bedanken voor de tijd die ze hebben vrijgemaakt voor de beoordeling van
dit proefschrift.
Mijn kamergenoten uit het UMCU. Beste Shirley, Tanja en Marloes, dank voor de
gezellige tijd die we samen hebben gehad. Jullie hebben deze klus allemaal al
geklaard, hopelijk gaat het mij net zo goed af als jullie.
Cora Arts, jij was mijn grote voorbeeld als onderzoeker bij de vaten in het UMC en
nu ben je dat weer als oudere assistent. Leuk dat we naast collega's ook vriendin-
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De chirurgen en assistenten in het Amphia Ziekenhuis in Breda. Dank voor jullie
begrip en steun. Jullie zijn een geweldige groep om mee te werken.
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Lieve Marieke, Jobien en Roelie, sorry dat ik het de laatste tijd vaak te druk had om
iets af te spreken. Dat wordt hopelijk nu weer beter. Dank voor jullie gezelligheid,
steun en begrip.
Karen Ringenaldus, paranimf. Lieve Ka, je bent een geweldige vriendin. Dank voor
al je steun en gezelligheid in de toch vaak hectische periodes. Ik vind het ontzettend
leuk dat je mijn paranimf wilt zijn.
Lieve Ivonne, jij weet wel hoe belangrijk je voor me bent. Dank voor alles, je bent
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vader en moeder tegelijk en daar ben ik trots op. Dit boekje is uiteraard ook voor
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